Case number 1:22-cv-00061
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 22, 2025 | 873 | AGREED ORDER granting (870) Motion in case 1:22-cv-00061-TSK-JPM; granting 514 Motion in case 1:24-md-03103-TSK-JPM. Signed by Chief District Judge Thomas S. Kleeh on 04/22/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 04/22/2025) (1) |
| Apr 22, 2025 | 874 | STIPULATION AND ORDER VACATING PERMANENT INJUNCTION PREVIOUSLY ISSUED BY THE COURT IN THIS MATTER AND DISMISSING ALL CLAIMS AND COUNTERCLAIMS WITH PREJUDICE. Signed by Chief District Judge Thomas S. Kleeh on 04/22/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(snc) (Entered: 04/22/2025) (4) |
| Apr 22, 2025 | 875 | REPORT to USPTO on the filing or determination of an action regarding 874 Order and 1 Complaint. (snc) (Entered: 04/22/2025) (2) |
| Apr 21, 2025 | 872 | STIPULATION AND [PROPOSED] ORDER VACATING PERMANENT INJUNCTION PREVIOUSLY ISSUED BY THE COURT IN THIS MATTER AND DISMISSING ALL CLAIMS AND COUNTERCLAIMS WITH PREJUDICE by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 04/21/2025) (5) |
| Apr 17, 2025 | 871 | MANDATE of USCA for the Federal Circuit as to (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (snc) (Entered: 04/17/2025) (2) |
| Apr 15, 2025 | 870 | Joint MOTION to Lift the March 26, 2024 Order's Prosecution Bar by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 04/15/2025) (0) |
| Apr 8, 2025 | 868 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC. (Documents produced on 3.18.25). Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 04/08/2025) (2) |
| Apr 8, 2025 | 869 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC. (Documents produced on 3.21.25). Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 04/08/2025) (2) |
| Apr 2, 2025 | 864 | MOTION to Withdraw as Attorney EVAN T. LEO'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Pogue, David) (Entered: 04/02/2025) (4) |
| Apr 2, 2025 | 865 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 505 ) Signed by Chief District Judge Thomas S. Kleeh on 04/02/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 04/02/2025) (1) |
| Apr 2, 2025 | 866 | ORDER. The motion for Evan T. Leo to withdraw as counsel is GRANTED (ECF No. 507 ). Evan T. Leo shall be TERMINATED as counsel of record in this matter. Signed by Chief District Judge Thomas S. Kleeh on 04/02/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(snc) (Entered: 04/02/2025) (1) |
| Apr 2, 2025 | 867 | VACATED based on Order 874 entered on 04/22/2025. STIPULATION REGARDING NOTICE. Signed by Chief District Judge Thomas S. Kleeh on 04/02/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) Modified on 4/22/2025 (snc). (Entered: 04/02/2025) (0) |
| Apr 1, 2025 | 862 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Pogue, David) (Entered: 04/01/2025) (0) |
| Mar 7, 2025 | 860 | MANDATE of USCA for the Federal Circuit as to (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD., (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd. (snc) (Entered: 03/07/2025) (1) |
| Mar 7, 2025 | 861 | MANDATE of USCA for the Federal Circuit as to (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG. (snc) (Entered: 03/07/2025) (1) |
| Mar 6, 2025 | 859 | ORDER. The 164 motion is DENIED WITHOUT PREJUDICE. Associated cases: (796) in case 1:22-cv-00061-TSK-JPM; (186) in case 1:23-cv-00089-TSK-JPM; (239) in case 1:23-cv-00094-TSK-JPM; (236) in case 1:23-cv-00097-TSK-JPM; (221) in case 1:23-cv-00106-TSK-JPM; (164) in case 1:24-md-03103-TSK-JPM; (184) in case 1:24-cv-00039-TSK-JPM; (17) in case 1:24-cv-00053-TSK; in case 1:24-cv-00085-TSK. Signed by Chief District Judge Thomas S Kleeh on 3/6/2025. (dk) (Entered: 03/06/2025) (1) |
| Mar 5, 2025 | 857 | OPINION OF USCA FOR THE FEDERAL CIRCUIT as to (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA Decision: AFFIRMED (dk) (Entered: 03/05/2025) (10) |
| Mar 5, 2025 | 858 | JUDGMENT OF THE USCA FOR THE FEDERAL CIRCUIT as to (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (dk) (Entered: 03/05/2025) (1) |
| Feb 28, 2025 | 856 | ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL (ECF NO. 486 ). Attorney John D. Pizzo terminated. in cases 1:24-md-03103-TSK-JPM and 1:22-cv-00061-TSK-JPM. Signed by Chief District Judge Thomas S. Kleeh on 02/28/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 02/28/2025) (1) |
| Feb 26, 2025 | 854 | MOTION to Withdraw as Attorney (John Pizzo) by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 02/26/2025) (2) |
| Feb 26, 2025 | 855 | MOTION to Withdraw as Attorney (John D. Pizzo) by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 02/26/2025) (2) |
| Jan 29, 2025 | 852 | OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) (30) |
| Jan 29, 2025 | 853 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) (1) |
| Jan 14, 2025 | 850 | MOTION to Withdraw as Attorney - Thomas H Ehrich by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 01/14/2025) (2) |
| Jan 14, 2025 | 851 | ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL (ECF NO. 467 ). Attorney Thomas H. Ehrich terminated in case 1:24-md-03103-TSK-JPM and in case 1:22-cv-00061-TSK-JPM. Signed by Chief District Judge Thomas S. Kleeh on 01/14/2025. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 01/14/2025) (1) |
| Dec 12, 2024 | 848 | MOTION to Withdraw as Attorney ANISH R. DESAI, KATHRYN LEICHT, KELLIE VAN BECK, MATTHEW D. SEIGER, NATALIE C. KENNEDY, TOM YU, AND ZHEN LIN'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 12/12/2024) (4) |
| Dec 12, 2024 | 849 | ORDER. For good cause, the following motions to withdraw are GRANTED: ECF Nos. 426 , 427 , 438 . The Clerk SHALL terminate Jennifer Brooks Crozier, Rocco Recce, Anish R. Desai, Kathryn Leicht, Kellie Van Beck, Matthew D. Sieger, Natalie C. Kennedy, Tom Yu, and Zhen Lin as counsel of record in this matter. Additionally, for good cause, the following motions to seal are GRANTED: ECF Nos. 429 , 431 . Signed by Chief District Judge Thomas S. Kleeh on 12/12/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 12/12/2024) (1) |
| Dec 9, 2024 | 847 | NOTICE of Change of Address by David R. Pogue Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 12/09/2024) (3) |
| Dec 4, 2024 | 843 | NOTICE of Change of Address by David R. Pogue Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 12/04/2024) (3) |
| Dec 4, 2024 | 844 | MOTION to Withdraw as Attorney JENNIFER BROOKS CROZIER'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 12/04/2024) (4) |
| Dec 4, 2024 | 845 | MOTION to Withdraw as Attorney ROCCO RECCE'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 12/04/2024) (4) |
| Dec 4, 2024 | 846 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. documents bearing production numbers BBI-AFL-BLA0002802 BBI-AFL-BLA0021883. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 12/04/2024) (2) |
| Nov 15, 2024 | 842 | ORDER GRANTING MOTIONS TO WITHDRAW AS COUNSEL (ECF NOS. 394 , 395 ). Signed by Chief District Judge Thomas S. Kleeh on 11/15/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 11/15/2024) (1) |
| Nov 14, 2024 | 840 | MOTION to Withdraw as Attorney SEAN M. DOUGLASS' MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 11/14/2024) (4) |
| Nov 14, 2024 | 841 | MOTION to Withdraw as Attorney REBECCA CARTER'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 11/14/2024) (4) |
| Nov 6, 2024 | 839 | REPLY to Response to Motion re (835 in 1:22-cv-00061-TSK-JPM) MOTION for Leave to File Reply in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 11/06/2024) (6) |
| Oct 31, 2024 | 838 | ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL (ECF NO. 378 ). Ms. Anderson shall be TERMINATED as counsel of record in this matter. Signed by Chief District Judge Thomas S. Kleeh on 10/31/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 10/31/2024) (1) |
| Oct 30, 2024 | 836 | MOTION to Withdraw as Attorney HAYLEE BERNAL ANDERSON'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 10/30/2024) (4) |
| Oct 30, 2024 | 837 | RESPONSE in Opposition re (835 in 1:22-cv-00061-TSK-JPM, 377 in 1:24-md-03103-TSK-JPM) MOTION for Leave to File Reply in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 10/30/2024) (9) |
| Oct 22, 2024 | 835 | MOTION for Leave to File Reply in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Reply in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 10/22/2024) () (4) |
| Oct 22, 2024 | 835 | MOTION for Leave to File Reply in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Reply in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 10/22/2024) (Attachment Reply in Support of Regeneron's Objections to the Magistrate Jud) (16) |
| Oct 15, 2024 | 834 | MEMORANDUM Defendants Response to Regenerons Objections to Magistrate Judge Mazzones Order Denying Regenerons Motion to Lift the Prosecution Bar by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re (833 in 1:22-cv-00061-TSK-JPM) Objections, . (Attachments: # 1 Exhibit Exhibit A)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 10/15/2024) () (29) |
| Oct 15, 2024 | 834 | MEMORANDUM Defendants Response to Regenerons Objections to Magistrate Judge Mazzones Order Denying Regenerons Motion to Lift the Prosecution Bar by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re (833 in 1:22-cv-00061-TSK-JPM) Objections, . (Attachments: # 1 Exhibit Exhibit A)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 10/15/2024) (Exhibit Exhibit A) (19) |
| Oct 1, 2024 | 833 | OBJECTIONS to (828 in 1:22-cv-00061-TSK-JPM) Order, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit Declaration of Ellen Oberwetter in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 10/01/2024) () (27) |
| Oct 1, 2024 | 833 | OBJECTIONS to (828 in 1:22-cv-00061-TSK-JPM) Order, by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit Declaration of Ellen Oberwetter in Support of Regeneron's Objections to the Magistrate Judge's Order Denying Motion to Lift the March 26, 2024 Order's Prosecution Bar)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 10/01/2024) (Exhibit Declaration of Ellen Oberwetter in Support of Regeneron's Objection) (2) |
| Sep 27, 2024 | 831 | RESPONSE to Motion re (27 in 1:24-cv-00053-TSK, 334 in 1:24-md-03103-TSK-JPM, 261 in 1:23-cv-00106-TSK-JPM, 266 in 1:23-cv-00097-TSK-JPM, 254 in 1:24-cv-00039-TSK-JPM, 278 in 1:23-cv-00094-TSK-JPM, 215 in 1:23-cv-00089-TSK-JPM) MOTION for Status Conference filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 09/27/2024) (5) |
| Sep 27, 2024 | 832 | REPLY to Response to Motion re (824 in 1:22-cv-00061-TSK-JPM) MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing Defendants Biocon Biologics Inc.s and Mylan Pharmaceuticals Inc.s Reply in Support of Motion To Unseal Portions of the August 13, 2024 Hearing Transcript and Related Briefing filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 09/27/2024) (6) |
| Sep 23, 2024 | 830 | TRANSCRIPT of Proceedings held on 9/5/2024, before Judge Mazzone. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 10/15/2024. Redacted Transcript Deadline set for 10/24/2024. Release of Transcript Restriction set for 12/23/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(ck) (Entered: 09/23/2024) (0) |
| Sep 20, 2024 | 828 | AMENDED ORDER DENYING REGENERON PHARMACEUTICALS, INC.'S MOTION 275 TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR. Signed by Magistrate Judge James P. Mazzone on 09/20/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 09/20/2024) (7) |
| Sep 20, 2024 | 829 | Memorandum in Opposition re (824 in 1:22-cv-00061-TSK-JPM, 327 in 1:24-md-03103-TSK-JPM) MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing filed by Amgen, Inc., Amgen, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM, 1:24-cv-00039-TSK-JPM(McMillan, Stuart) (Entered: 09/20/2024) (6) |
| Sep 18, 2024 | 827 | MOTION Joinder in Motion for Status Conference by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/18/2024) (3) |
| Sep 17, 2024 | 826 | ORDER DENYING REGENERON PHARMACEUTICALS, INC.'S MOTION 275 TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR. Signed by Magistrate Judge James P. Mazzone on 09/17/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 09/17/2024) (7) |
| Sep 16, 2024 | 825 | ORDER of USCA for the Federal Circuit as to 259 Notice of Appeal filed by Samsung Bioepis Co., Ltd., 190 Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., 258 Notice of Appeal filed by Samsung Bioepis, CO., LTD., 175 Notice of Appeal, filed by Samsung Bioepis, CO., LTD., 203 Notice of Appeal, filed by Formycon AG, 261 Notice of Appeal filed by Formycon AG, 176 Notice of Appeal, filed by Samsung Bioepis Co., Ltd. (snc) Modified to adjust filing date on 9/16/2024 (snc). (Entered: 09/16/2024) (3) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) () (8) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) (Exhibit 1) (6) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) (Exhibit 2) (8) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) (Exhibit 3) (29) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) (Exhibit 4) (6) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) (Exhibit 5) (5) |
| Sep 6, 2024 | 824 | MOTION to Unseal Document Portions of the August 13, 2024 Hearing Transcript and Related Briefing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Appendix Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 09/06/2024) (Appendix Proposed Order) (3) |
| Sep 5, 2024 | 823 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Magistrate Judge James P. Mazzone: Oral Argument Hearing held on 9/5/2024 re ( 812 in 1:22-cv-00061-TSK-JPM, 275 in 1:24-md-03103-TSK-JPM) MOTION TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR AS TO CERTAIN ATTORNEYS AND LAW FIRMS filed by Regeneron Pharmaceuticals, Inc.. (Tape #WHG Mazzone 1 24 md 3103 and 1 22 cv 61 Regeneron v Mylan 9 5 24) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(ag) (Entered: 09/05/2024) (0) |
| Sep 3, 2024 | 822 | ORDER GRANTING MOTIONS TO WITHDRAW. For good cause, they are GRANTED (ECF Nos. 323 , 324 ). Renee M. Griffin and Yi Zhang shall be TERMINATED as counsel of record. Signed by Chief District Judge Thomas S. Kleeh on 09/03/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 09/03/2024) (1) |
| Aug 30, 2024 | 820 | MOTION to Withdraw as Attorney RENEE M. GRIFFIN'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/30/2024) (4) |
| Aug 30, 2024 | 821 | MOTION to Withdraw as Attorney YI ZHANG'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/30/2024) (4) |
| Aug 22, 2024 | 819 | ORDER GRANTING UNOPPOSED MOTION 320 TO CONTINUE HEARING. Accordingly, the hearing currently set for August 23, 2024, is CANCELLED. The oral argument/evidentiary hearing regarding Regeneron's Motion 275 to Lift the March 26, 2024 Order's Prosecution Bar is NOW SET for September 5, 2024, at 10:00 a.m. in the Wheeling Magistrate Judge Courtroom, 4th Floor, before Magistrate Judge James P. Mazzone. Signed by Magistrate Judge James P. Mazzone on 08/22/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 08/22/2024) (1) |
| Aug 21, 2024 | 818 | Consent MOTION to Continue Unopposed Motion to Continue Hearing by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 08/21/2024) (3) |
| Aug 13, 2024 | 817 | ORDER SETTING ORAL ARGUMENT/EVIDENTIARY HEARING. An oral argument/evidentiary hearing is SET for August 23, 2024, at 10:00 a.m. in the Wheeling Magistrate Judge Courtroom, 4th Floor, before Magistrate Judge James P. Mazzone. Signed by Magistrate Judge James P. Mazzone on 08/13/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 08/13/2024) (1) |
| Aug 12, 2024 | 816 | ORDER OF REFERRAL. The 275 motion is REFERRED to Magistrate Judge James P. Mazzone for disposition. Signed by Chief District Judge Thomas S. Kleeh on 08/12/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Main Document 313 replaced on 8/12/2024 to correct typo) (snc). (Entered: 08/12/2024) (1) |
| Aug 2, 2024 | 815 | NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) () (4) |
| Aug 2, 2024 | 815 | NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) (Attachment July 23, 2024 Order ('572 patent)) (6) |
| Aug 2, 2024 | 815 | NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) (Attachment July 30, 2024 Judgment ('601 patent)) (4) |
| Jul 30, 2024 | 814 | REPLY to Response to Motion re (812 in 1:22-cv-00061-TSK-JPM) MOTION TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR AS TO CERTAIN ATTORNEYS AND LAW FIRMS filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 07/30/2024) (6) |
| Jul 29, 2024 | 813 | RESPONSE in Opposition re (812 in 1:22-cv-00061-TSK-JPM) MOTION TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR AS TO CERTAIN ATTORNEYS AND LAW FIRMS filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 07/29/2024) (5) |
| Jul 15, 2024 | 812 | MOTION TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR AS TO CERTAIN ATTORNEYS AND LAW FIRMS by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 07/15/2024) () (6) |
| Jul 15, 2024 | 812 | MOTION TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR AS TO CERTAIN ATTORNEYS AND LAW FIRMS by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 07/15/2024) (Exhibit 1) (28) |
| Jul 15, 2024 | 812 | MOTION TO LIFT THE MARCH 26, 2024 ORDER'S PROSECUTION BAR AS TO CERTAIN ATTORNEYS AND LAW FIRMS by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 07/15/2024) (Proposed Order) (2) |
| Jul 9, 2024 | 811 | NOTICE by Celltrion, Inc. of Withdrawal (Davis, Laura) (Entered: 07/09/2024) (2) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) () (5) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 1) (3) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 2) (2) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 3) (3) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 4) (2) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 5) (4) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 6) (2) |
| Jul 3, 2024 | 810 | REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 7) (2) |
| Jun 28, 2024 | 808 | ORDER ON MOTION of USCA for the FEDERAL CIRCUIT as to 801 in 1:22-cv-00061-TSK-JPM and 190 in 1:24-md-03103-TSK-JPM Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (snc) (Entered: 06/28/2024) (2) |
| Jun 28, 2024 | 809 | USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING re (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG. USCA for the Federal Circuit USCA Case Number: 2024-2019. Case Manager: M. Ames. (Clerk confirmed with Federal Circuit (J. Phillips) that this second appeal was opened in error and that a termination letter would be issued.) (dk) (Entered: 07/01/2024) (4) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) () (8) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 1) (5) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 2) (7) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 3) (6) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 4) (3) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 5) (4) |
| Jun 26, 2024 | 807 | RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Proposed Order) (4) |
| Jun 25, 2024 | 806 | USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING re 801 in 1:22-cv-00061-TSK-JPM and 190 in 1:24-md-03103-TSK-JPM. Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. Federal Circuit USCA Case Number: 2024-2002. (snc) (Entered: 06/25/2024) (4) |
| Jun 24, 2024 | 803 | ***SEALED***ORDER. Signed by Magistrate Judge James P. Mazzone on 06/24/2024. (Copy to counsel of record only) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/24/2024) (0) |
| Jun 21, 2024 | 801 | Notice of Appeal* (1) |
| Jun 21, 2024 | 799 | Redacted Order Granting Motion for Permanent Injunction. Signed by Chief District Judge Thomas S. Kleeh on 06/11/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (Filed as public order per Chambers (rr)) (snc) (Entered: 06/21/2024) (30) |
| Jun 21, 2024 | 800 | ORDER FOR INJUNCTIVE RELIEF AGAINST BIOCON AND MYLAN. Signed by Chief District Judge Thomas S. Kleeh on 06/21/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/21/2024) (3) |
| Jun 21, 2024 | 802 | Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 190 in 1:24-md-03103-TSK-JPM and 801 in 1:22-cv-00061-TSK-JPM Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Judgment) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/21/2024) () (1) |
| Jun 21, 2024 | 802 | Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 190 in 1:24-md-03103-TSK-JPM and 801 in 1:22-cv-00061-TSK-JPM Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Judgment) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/21/2024) (Attorney List) (24) |
| Jun 21, 2024 | 802 | Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 190 in 1:24-md-03103-TSK-JPM and 801 in 1:22-cv-00061-TSK-JPM Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Judgment) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/21/2024) (Docket Sheet) (30) |
| Jun 21, 2024 | 802 | Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 190 in 1:24-md-03103-TSK-JPM and 801 in 1:22-cv-00061-TSK-JPM Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Judgment) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/21/2024) (Notice of Appeal) (4) |
| Jun 21, 2024 | 802 | Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 190 in 1:24-md-03103-TSK-JPM and 801 in 1:22-cv-00061-TSK-JPM Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Judgment) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/21/2024) (Judgment) (1) |
| Jun 20, 2024 | 797 | MOTION to Withdraw (Jeffrey A. Marx) by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 06/20/2024) () (3) |
| Jun 20, 2024 | 798 | ORDER GRANTING MOTION TO WITHDRAW. ( 797 in 1:22-cv-00061-TSK-JPM, 182 in 1:24-md-03103-TSK-JPM). Signed by Chief District Judge Thomas S. Kleeh on 06/20/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/20/2024) (1) |
| Jun 20, 2024 | 797 | MOTION to Withdraw (Jeffrey A. Marx) by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM(O'Brien, William) (Entered: 06/20/2024) (Proposed Order) (1) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) () (4) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Supplement Memo ISO) (8) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Proposed Order) (3) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 1) (2) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 2) (5) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 3) (9) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 4) (13) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 5) (3) |
| Jun 12, 2024 | 796 | MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 6) (5) |
| Jun 11, 2024 | 793 | ORDER OVERRULING OBJECTIONS TO MAGISTRATE JUDGE'S ORDER. The motion 126 for an extension is GRANTED, and Defendants' response 143 is deemed FILED. Regeneron's motion 153 for leave to file a reply is DENIED. Regeneron's objections 62 to the Magistrate Judge's order are OVERRULED. Signed by Chief District Judge Thomas S. Kleeh on 06/11/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/11/2024) (4) |
| Jun 11, 2024 | 794 | ***SEALED***ORDER GRANTING MOTION FOR PERMANENT INJUNCTION. Signed by Chief District Judge Thomas S. Kleeh on 06/11/2024. (Copy to counsel for Regeneron, Mylan and Biocon ONLY) Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/11/2024) (0) |
| Jun 11, 2024 | 795 | CLERK'S JUDGMENT. Signed by Clerk of Court on 06/11/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:22-cv-00061-TSK-JPM (snc) (Entered: 06/11/2024) (1) |
| Jun 5, 2024 | 792 | Memorandum in Opposition re (790 in 1:22-cv-00061-TSK-JPM) MOTION for Leave to File Reply in Support of Regeneron's Objections to Magistrate Judge's Order [Defendants Opposition to Regenerons Motion for Leave to File a Reply in Support Of Regenerons Objections to The March 26, 2024 Sanctions Order] filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Exhibit 1)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 06/05/2024) () (13) |
| Jun 5, 2024 | 792 | Memorandum in Opposition re (790 in 1:22-cv-00061-TSK-JPM) MOTION for Leave to File Reply in Support of Regeneron's Objections to Magistrate Judge's Order [Defendants Opposition to Regenerons Motion for Leave to File a Reply in Support Of Regenerons Objections to The March 26, 2024 Sanctions Order] filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Exhibit 1)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 06/05/2024) (Exhibit Exhibit 1) (6) |
| May 31, 2024 | 790 | MOTION for Leave to File Reply in Support of Regeneron's Objections to Magistrate Judge's Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Regeneron's Reply in Support of Its Objections to the Magistrate Judge's Order Granting Defendants' Motion for Sanctions)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/31/2024) () (5) |
| May 31, 2024 | 791 | Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) () (14) |
| May 31, 2024 | 790 | MOTION for Leave to File Reply in Support of Regeneron's Objections to Magistrate Judge's Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Regeneron's Reply in Support of Its Objections to the Magistrate Judge's Order Granting Defendants' Motion for Sanctions)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/31/2024) (Attachment Regeneron's Reply in Support of Its Objections to the Magistrate) (16) |
| May 31, 2024 | 791 | Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix A - Regeneron's Filings) (30) |
| May 31, 2024 | 791 | Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix B - Amgen's Filings) (30) |
| May 31, 2024 | 791 | Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix C - Mylan/Biocon's Filings) (30) |
| May 31, 2024 | 791 | Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis) (30) |
| May 30, 2024 | 789 | ORDER EXTENDING TEMPORARY RESTRAINING ORDER: granting 788 and 150 Motions. Signed by Chief District Judge Thomas S. Kleeh on 05/30/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM (snc) (Entered: 05/30/2024) (3) |
| May 29, 2024 | 788 | MOTION for Extension of Temporary Restraining Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/29/2024) () (6) |
| May 29, 2024 | 788 | MOTION for Extension of Temporary Restraining Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/29/2024) (Proposed Order) (3) |
| May 28, 2024 | 787 | ORDER GRANTING MOTION TO WITHDRAW. The Court GRANTS the motion 127 and DIRECTS the Clerk to terminate Attorney Abraham Varon from the list of attorneys in this case. Signed by Chief District Judge Thomas S. Kleeh on 05/28/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(snc) (Entered: 05/28/2024) (1) |
| May 24, 2024 | 786 | RESPONSE by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/24/2024) (30) |
| May 23, 2024 | 785 | RESPONSE to Motion re (783 in 1:22-cv-00061-TSK-JPM) MOTION for Extension of Time to File Response To Regenerons Objections To The Magistrate Judges Order Granting Defendants Motion For Sanctions filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/23/2024) () (4) |
| May 23, 2024 | 785 | RESPONSE to Motion re (783 in 1:22-cv-00061-TSK-JPM) MOTION for Extension of Time to File Response To Regenerons Objections To The Magistrate Judges Order Granting Defendants Motion For Sanctions filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/23/2024) (Exhibit 1) (4) |
| May 23, 2024 | 785 | RESPONSE to Motion re (783 in 1:22-cv-00061-TSK-JPM) MOTION for Extension of Time to File Response To Regenerons Objections To The Magistrate Judges Order Granting Defendants Motion For Sanctions filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/23/2024) (Exhibit 2) (28) |
| May 22, 2024 | 783 | MOTION for Extension of Time to File Response To Regenerons Objections To The Magistrate Judges Order Granting Defendants Motion For Sanctions by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/22/2024) () (4) |
| May 22, 2024 | 784 | MOTION to Withdraw as Attorney on behalf of Abraham Varon by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/22/2024) () (3) |
| May 22, 2024 | 784 | MOTION to Withdraw as Attorney on behalf of Abraham Varon by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/22/2024) (Proposed Order) (1) |
| May 22, 2024 | 783 | MOTION for Extension of Time to File Response To Regenerons Objections To The Magistrate Judges Order Granting Defendants Motion For Sanctions by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/22/2024) (Proposed Order) (1) |
| May 21, 2024 | 781 | ORDER REGARDING LIAISON COUNSEL. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) (Entered: 05/21/2024) (2) |
| May 21, 2024 | 782 | ORDER DENYING CERTAIN MOTIONS AS MOOT. Regeneron's motion for guidance 36 and Amgen's motion requesting an expedited status conference 20 are DENIED AS MOOT. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) Modified to unseal on 5/21/2024; Order was sealed in error. NEF regen. (dk). (Entered: 05/21/2024) (1) |
| May 20, 2024 | 780 | ORDER. The parties are DIRECTED to file, on or before May 31, 2024, written proposals indicating which matters are appropriate for collective pretrial consideration and disposition while the case is designated as an MDL. Signed by Chief District Judge Thomas S. Kleeh on 5/20/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 05/20/2024) (1) |
| May 17, 2024 | 776 | ORDER GRANTING MOTION FOR TEMPORARY RESTRAINING ORDER (ECF NO. 70 ). Signed by Chief District Judge Thomas S. Kleeh on 05/17/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM (snc) (Entered: 05/17/2024) (4) |
| May 17, 2024 | 777 | ORDER GRANTING 104 MOTION TO SEAL. Signed by Chief District Judge Thomas S. Kleeh on 05/17/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM (snc) (Entered: 05/17/2024) (2) |
| May 17, 2024 | 778 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh, Scheduling Conference held on 5/17/2024. (Court Reporter Cindy Knecht) Associated Cases: 1:24-md-03103-TSK et al. (dk) (Entered: 05/17/2024) (0) |
| May 17, 2024 | 779 | TRANSCRIPT of status conference held on 5/17/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 6/7/2024. Redacted Transcript Deadline set for 6/17/2024. Release of Transcript Restriction set for 8/15/2024. Associated Cases: 1:24-md-03103-TSK et al.(ck) (Entered: 05/17/2024) (22) |
| May 16, 2024 | 773 | MOTION for Leave to File UNDER SEAL by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/16/2024) () (3) |
| May 16, 2024 | 775 | REDACTION Regeneron's Objections to the Magistrate Judge's Order Granting Defendants' Motion for Sanctions [Dkt. No. 769] by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/16/2024) (30) |
| May 16, 2024 | 773 | MOTION for Leave to File UNDER SEAL by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Copland, Gordon) (Entered: 05/16/2024) (Proposed Order) (2) |
| May 15, 2024 | 772 | ORDER GRANTING CERTAIN MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 42 , 47 , 60 , 63 , 68 , 69 . Signed by Chief District Judge Thomas S. Kleeh on 05/15/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00097-TSK-JPM (snc) Modified on 7/12/2024 to unseal - NEF regenerated (snc). (Entered: 05/15/2024) (1) |
| May 14, 2024 | 770 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) () (4) |
| May 14, 2024 | 770 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) (Attachment Memorandum in Support) (6) |
| May 14, 2024 | 770 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) (Proposed Order) (1) |
| May 10, 2024 | 766 | ORDER DENYING MOTION TO EXCEED PAGE LIMIT AND MOTION TO SEAL (ECF NOS. 55 , 56 ). The objections are STRICKEN 57 . Signed by Chief District Judge Thomas S. Kleeh on 05/10/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM (snc) (Entered: 05/10/2024) (1) |
| May 10, 2024 | 767 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support of Motion for Leave to File Under Seal, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/10/2024) () (4) |
| May 10, 2024 | 768 | NOTICE by Regeneron Pharmaceuticals, Inc. Joint Notice of Pending Motions Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/10/2024) (14) |
| May 10, 2024 | 767 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support of Motion for Leave to File Under Seal, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/10/2024) (Memorandum of Law in Support of Motion for Leave to File Under Seal) (6) |
| May 10, 2024 | 767 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support of Motion for Leave to File Under Seal, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/10/2024) (Proposed Order) (2) |
| May 9, 2024 | 762 | ORDER GRANTING INTERVENOR AMGEN'S UNOPPOSED MOTION TO UNSEAL MARCH 26, 2024 ORDER. Signed by Magistrate Judge James P. Mazzone on 05/09/2024. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM (snc) (Entered: 05/09/2024) (1) |
| May 9, 2024 | 763 | MOTION to Exceed Page Limit for Objections to Magistrate Judge's Order by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/09/2024) (5) |
| May 9, 2024 | 764 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/09/2024) () (4) |
| May 9, 2024 | 764 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/09/2024) (Attachment Memorandum in Support) (6) |
| May 9, 2024 | 764 | MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Ruby, Steven) (Entered: 05/09/2024) (Proposed Order) (1) |
| May 8, 2024 | 761 | MOTION to Unseal Document (724 in 1:22-cv-00061-TSK-JPM) MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFF'S PROTECTIVE ORDER VIOLATIONS filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. by AMGEN USA, INC.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Tinney, John) Modified on 5/8/2024 to correct docket entry number (snc). (Entered: 05/08/2024) () (3) |
| May 8, 2024 | 761 | MOTION to Unseal Document (724 in 1:22-cv-00061-TSK-JPM) MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFF'S PROTECTIVE ORDER VIOLATIONS filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. by AMGEN USA, INC.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Tinney, John) Modified on 5/8/2024 to correct docket entry number (snc). (Entered: 05/08/2024) (Proposed Order) (1) |
| May 7, 2024 | 755 | REPLY to Response to Motion re (207 in 1:23-cv-00094-TSK-JPM, 217 in 1:23-cv-00097-TSK-JPM, 168 in 1:23-cv-00089-TSK-JPM, 131 in 1:24-cv-00039-TSK, 754 in 1:22-cv-00061-TSK-JPM, 36 in 1:24-md-03103-TSK, 189 in 1:23-cv-00106-TSK-JPM) MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/07/2024) (4) |
| May 7, 2024 | 756 | MOTION for Leave to File Inadvertently Omitted Exhibits UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Pogue, David) (Entered: 05/07/2024) () (4) |
| May 7, 2024 | 756 | MOTION for Leave to File Inadvertently Omitted Exhibits UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM(Pogue, David) (Entered: 05/07/2024) (Proposed Order) (1) |
| May 3, 2024 | 754 | MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/03/2024) (6) |
| Apr 26, 2024 | 752 | ORDER CANCELING STATUS CONFERENCES. On April 11, 2024, each of the cases became member cases of the MDL Case No. 1:24-md-3013. For that reason, the status conferences are CANCELED. Signed by Chief District Judge Thomas S. Kleeh on 4/26/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 04/26/2024) (1) |
| Apr 26, 2024 | 753 | PRETRIAL ORDER #1: INITIAL SCHEDULING CONFERENCE. Scheduling Conference is set for 5/17/2024 11:00 AM by Zoom Videoconference before Chief District Judge Thomas S. Kleeh. Signed by Chief District Judge Thomas S. Kleeh on 4/26/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 04/26/2024) (10) |
| Apr 24, 2024 | 749 | ORDER CONTINUING MAY 2, 2024 PERMANENT AND PRELIMINARY INJUNCTION HEARINGS. The Court will reschedule the preliminary and permanent injunction hearings, if necessary, by separate order. For reasons stated herein, the parties' Joint Motion for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings is also DENIED (ECF No. 9 ). Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. Associated Cases: 1:24-md-03103-TSK et al. (dk) (Entered: 04/24/2024) (2) |
| Apr 24, 2024 | 750 | ***SEALED*** ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 747 . Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. (Copy to Counsel) Associated Cases: 1:24-md-03103-TSK, 1:22-cv-00061-TSK-JPM (dk) (Entered: 04/24/2024) (0) |
| Apr 23, 2024 | 748 | Joint MOTION for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 04/23/2024) (9) |
| Apr 18, 2024 | 746 | ***SEALED***ORDER. Signed by Magistrate Judge James P. Mazzone on 4/18/2024. Copy to counsel. (mas) (Entered: 04/18/2024) (0) |
| Apr 17, 2024 | 744 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/17/2024. Copy to Counsel. (mas) (Entered: 04/17/2024) (0) |
| Apr 12, 2024 | 741 | USCA for the Federal Circuit Order Dismissing Appeals as to 676 Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., 677 Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. Issued as Mandate as to Appeal Nos. 2024-1402 and 2024-1405. (dk) (Entered: 04/12/2024) (2) |
| Apr 12, 2024 | 742 | ***SEALED***ORDER. Signed by Magistrate Judge James P. Mazzone on 4/12/2024. Copy to counsel. (mas) (Entered: 04/12/2024) (0) |
| Apr 8, 2024 | 737 | NOTICE by Regeneron Pharmaceuticals, Inc. of Appearance of Jordan L. Damron (Franks, Raymond) (Entered: 04/08/2024) (2) |
| Apr 8, 2024 | 738 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/8/2024. Copy to counsel. (mas) (Entered: 04/08/2024) (0) |
| Apr 8, 2024 | 739 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Christopher Spadea. (Pogue, David) (Entered: 04/08/2024) (1) |
| Apr 5, 2024 | 734 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/5/2024. Copy to counsel. (cmd) (Entered: 04/05/2024) (0) |
| Apr 5, 2024 | 735 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/5/2024. Copy to counsel.(cmd) (Entered: 04/05/2024) (0) |
| Apr 5, 2024 | 736 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/5/2024. (Copy to counsel of record by email). (mas) (Entered: 04/05/2024) (0) |
| Apr 4, 2024 | 732 | RESPONSE to 726 Regeneron's Emergency Motion to Compel by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Defendants' Response to Regeneron's Emergency Motion to Compel, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9)(O'Brien, William) Modified on 4/5/2024 (cmd). (Entered: 04/04/2024) (0) |
| Apr 4, 2024 | 733 | Emergency MOTION for Clarification of and Extension of Time to Object to 724 March 26, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Emergency Motion for Clarification of and Extension of Time to Object to March 26, 2024 Order)(Pogue, David) Modified on 4/5/2024 (cmd). (Entered: 04/04/2024) (0) |
| Apr 3, 2024 | 731 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Matthew Erick. (Ruby, Steven) (Entered: 04/03/2024) (1) |
| Apr 2, 2024 | 728 | SEALED ORDER OF REFERRAL. (Copy emailed to counsel of record and referral Judge Mazzonne). Signed by Chief District Judge Thomas S Kleeh on 4/2/2024. (mas) (Entered: 04/02/2024) (0) |
| Apr 2, 2024 | 729 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/2/2024. (Emailed to Counsel) (dk) (Entered: 04/02/2024) (0) |
| Apr 2, 2024 | 730 | ***SEALED*** ORDER. Signed by Magistrate Judge James P. Mazzone on 4/2/2024. Copy to counsel. (cmd) (Entered: 04/02/2024) (0) |
| Apr 1, 2024 | 727 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Ivo Abraham. (Ruby, Steven) (Entered: 04/01/2024) (1) |
| Mar 29, 2024 | 726 | EMERGENCY MOTION to Compel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Emergency Motion to Compel, # 3 Attachment Memorandum in Support of Regeneron's Emergency Motion to Compel, # 4 Exhibit 1, # 5 Exhibit 2, # 6 Exhibit 3, # 7 Exhibit 4, # 8 Exhibit 5, # 9 Exhibit 6, # 10 Exhibit 7, # 11 Exhibit 8, # 12 Exhibit 9, # 13 Exhibit 10, # 14 Exhibit 11, # 15 Exhibit 12, # 16 Exhibit 13, # 17 Exhibit 14, # 18 Exhibit 15, # 19 Exhibit 16, # 20 Proposed Order)(Pogue, David) Modified on 4/2/2024 (cmd). (Entered: 03/29/2024) (0) |
| Mar 26, 2024 | 724 | SEALED ORDER GRANTING MOTION 658 TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS. Signed by Magistrate Judge James P. Mazzone on 3/26/2024. (Emailed to Counsel) (dk) Modified to unseal per 762 Order on 5/9/2024 (snc). (Entered: 03/26/2024) (17) |
| Mar 26, 2024 | 725 | Request to Discontinue E-mail Notification. (Davis, Laura) (Entered: 03/26/2024) (0) |
| Mar 22, 2024 | 723 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 3/22/2024. Copy to counsel.(cmd) (Entered: 03/22/2024) (0) |
| Mar 21, 2024 | 722 | DEFENDANTS OPPOSITION TO 708 REGENERONS OPENING BRIEF IN SUPPORT OF MOTION FOR PERMANENT INJUNCTION by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Brief in Opp to Injunction, # 2 Affidavit Birkos Decl, # 3 Exhibit Birkos Ex 1-7, # 4 Exhibit Birkos Ex 8, part 1, # 5 Exhibit Birkos Ex 8 part 2, # 6 Exhibit Birkos Ex 8 part 3, # 7 Exhibit Birkos Ex 8 part 4, # 8 Exhibit Birkos Ex 9-11, # 9 Exhibit Birkos Ex 12, # 10 Exhibit Birkos Ex 13, # 11 Exhibit Birkos Ex 14, # 12 Exhibit Birkos Ex 15-23, # 13 Exhibit Birkos Ex 24-27, # 14 Exhibit Birkos Ex 28-32, # 15 Exhibit Birkos Ex 33-35, # 16 Affidavit Eric Decl and Exhibits 1-10, # 17 Affidavit Abraham Decl and App. A and B, # 18 Affidavit Spadea Decl, # 19 Exhibit Spadea Ex 1-10, # 20 Exhibit Spadea Ex 11-20, # 21 Exhibit Spadea Ex 21-30, # 22 Exhibit Spadea Ex 31-40, # 23 Exhibit Spadea Ex 41-50)(Copland, Gordon) Modified on 3/22/2024 (cmd). (Entered: 03/21/2024) (0) |
| Mar 8, 2024 | 719 | ORDER OF DISMISSAL WITH RESPECT TO PLAINTIFFS' SEVENTH, NINTH, AND ELEVENTH CAUSES OF ACTION. Signed by Chief District Judge Thomas S Kleeh on 3/8/2024. (dk) (Entered: 03/08/2024) (1) |
| Mar 8, 2024 | 720 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Notice of Deposition of Sean Sheridan). (O'Brien, William) (Entered: 03/08/2024) (2) |
| Mar 8, 2024 | 721 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Notice of Deposition of Kevin Clark). (O'Brien, William) (Entered: 03/08/2024) (2) |
| Mar 6, 2024 | 718 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Fourth Requests for the Production of Documents and Things to Regeneron). (Copland, Gordon) (Entered: 03/06/2024) (2) |
| Mar 5, 2024 | 715 | CERTIFICATE OF SERVICE by BIOCON BIOLOGICS INC. (Responses and Objections to Plaintiff's Fifth Requests for Production of Documents (Nos. 46-54)). (Copland, Gordon) (Entered: 03/05/2024) (1) |
| Mar 5, 2024 | 716 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responses and Objections to Plaintiff's Fifth Requests for Production of Documents (Nos. 46-54)). (Copland, Gordon) (Entered: 03/05/2024) (1) |
| Mar 5, 2024 | 717 | AGREED ORDER SETTING DEADLINES re 708 Motion for Permanent Injunction. Responses due by 3/21/2024. Replies due by 4/18/2024. Motion Hearing set for 5/2/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Status Conference set for 5/13/2024 12:00 PM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 3/5/2024. (dk) (Entered: 03/05/2024) (2) |
| Mar 4, 2024 | 714 | PROPOSED AGREED ORDER SETTING DEADLINES ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 03/04/2024) (3) |
| Feb 26, 2024 | 712 | ***SEALED*** ORDER granting 706 , 707 . Signed by Magistrate Judge James P. Mazzone on 2/26/2024. (Emailed to Counsel) (dk) (Entered: 02/26/2024) (0) |
| Feb 26, 2024 | 713 | ***SEALED*** ORDER granting 711 Motion to Seal. Signed by Magistrate Judge James P. Mazzone on 2/26/2024. (Emailed to Counsel) (dk) (Entered: 02/26/2024) (0) |
| Feb 23, 2024 | 709 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 2/23/2024. Copy emailed to counsel. (cmd) (Entered: 02/23/2024) (0) |
| Feb 23, 2024 | 710 | Other Document Regeneron's Opposition to Defendants' Motion to Seal Dkt. 702 filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 02/23/2024) (8) |
| Feb 22, 2024 | 708 | MOTION FOR PERMANENT INJUNCTION AND INCORPORATED MEMORANDUM OF LAW by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Motion for Permanent Injunction, # 3 Attachment Opening Brief In Support of Motion for Permanent Injunction, # 4 Exhibit Sheridan Declaration, part 1, # 5 Exhibit Sheridan Declaration, part 2, # 6 Exhibit Sheridan Declaration, part 3, # 7 Exhibit Sheridan Declaration, part 4, # 8 Exhibit Sheridan Declaration, part 5, # 9 Exhibit Sheridan Declaration, part 6, # 10 Exhibit Sheridan Declaration, part 7, # 11 Exhibit Sheridan Declaration, part 8, # 12 Exhibit Sheridan Declaration, part 9, # 13 Exhibit Sheridan Declaration, part 10, # 14 Exhibit Sheridan Declaration, part 11, # 15 Exhibit Sheridan Declaration, part 12, # 16 Exhibit Clark Declaration, # 17 Exhibit Kayali Declaration, # 18 Proposed Order)(Pogue, David) Modified on 2/23/2024 (cmd). (Entered: 02/22/2024) (0) |
| Feb 21, 2024 | 703 | *SEALED* Modified on 2/29/2024 to remove document - transcript was accidentally filed in the wrong case (kac). (Entered: 02/21/2024) (0) |
| Feb 21, 2024 | 704 | TRANSCRIPT of motion hearing held on 2/15/2024, before Judge Mazzone. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 3/13/2024. Redacted Transcript Deadline set for 3/25/2024. Release of Transcript Restriction set for 5/21/2024. (ck) (Entered: 02/21/2024) (90) |
| Feb 21, 2024 | 705 | *SEALED* TRANSCRIPT of Sealed Hearing held on 2/15/2024, before Judge Mazzone. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 02/21/2024) (0) |
| Feb 16, 2024 | 701 | RESPONSE to Motion re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 02/16/2024) () (5) |
| Feb 16, 2024 | 701 | RESPONSE to Motion re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 02/16/2024) (Proposed Order) (1) |
| Feb 15, 2024 | 699 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Magistrate Judge James P. Mazzone: Evidentiary Hearing re 658 MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFF'S PROTECTIVE ORDER VIOLATIONS filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. held on 2/15/2024. (Court Reporter C. Knecht) (ag) (Entered: 02/15/2024) (0) |
| Feb 15, 2024 | 700 | CLERK'S EXHIBIT LIST from 2/15/2024 Evidentiary Hearing.(ag) (Additional attachment(s) added on 2/15/2024: # 1 Defendant Exhibit 1 (slides 1-30), # 2 Defendant Exhibit 1 (slides 31-69), # 3 Plaintiff Exhibit 1, # 4 Plaintiff Exhibit 2, # 5 Plaintiff Exhibit 3, # 6 Plaintiff SEALED Exhibit 4) (ag). (Entered: 02/15/2024) (0) |
| Feb 15, 2024 | 700 | CLERK'S EXHIBIT LIST from 2/15/2024 Evidentiary Hearing.(ag) (Additional attachment(s) added on 2/15/2024: # 1 Defendant Exhibit 1 (slides 1-30), # 2 Defendant Exhibit 1 (slides 31-69), # 3 Plaintiff Exhibit 1, # 4 Plaintiff Exhibit 2, # 5 Plaintiff Exhibit 3, # 6 Plaintiff SEALED Exhibit 4) (ag). (Entered: 02/15/2024) (Defendant Exhibit 1 (slides 1-30)) (30) |
| Feb 15, 2024 | 700 | CLERK'S EXHIBIT LIST from 2/15/2024 Evidentiary Hearing.(ag) (Additional attachment(s) added on 2/15/2024: # 1 Defendant Exhibit 1 (slides 1-30), # 2 Defendant Exhibit 1 (slides 31-69), # 3 Plaintiff Exhibit 1, # 4 Plaintiff Exhibit 2, # 5 Plaintiff Exhibit 3, # 6 Plaintiff SEALED Exhibit 4) (ag). (Entered: 02/15/2024) (Defendant Exhibit 1 (slides 31-69)) (30) |
| Feb 15, 2024 | 700 | CLERK'S EXHIBIT LIST from 2/15/2024 Evidentiary Hearing.(ag) (Additional attachment(s) added on 2/15/2024: # 1 Defendant Exhibit 1 (slides 1-30), # 2 Defendant Exhibit 1 (slides 31-69), # 3 Plaintiff Exhibit 1, # 4 Plaintiff Exhibit 2, # 5 Plaintiff Exhibit 3, # 6 Plaintiff SEALED Exhibit 4) (ag). (Entered: 02/15/2024) (Plaintiff Exhibit 1) (30) |
| Feb 15, 2024 | 700 | CLERK'S EXHIBIT LIST from 2/15/2024 Evidentiary Hearing.(ag) (Additional attachment(s) added on 2/15/2024: # 1 Defendant Exhibit 1 (slides 1-30), # 2 Defendant Exhibit 1 (slides 31-69), # 3 Plaintiff Exhibit 1, # 4 Plaintiff Exhibit 2, # 5 Plaintiff Exhibit 3, # 6 Plaintiff SEALED Exhibit 4) (ag). (Entered: 02/15/2024) (Plaintiff Exhibit 2) (1) |
| Feb 15, 2024 | 700 | CLERK'S EXHIBIT LIST from 2/15/2024 Evidentiary Hearing.(ag) (Additional attachment(s) added on 2/15/2024: # 1 Defendant Exhibit 1 (slides 1-30), # 2 Defendant Exhibit 1 (slides 31-69), # 3 Plaintiff Exhibit 1, # 4 Plaintiff Exhibit 2, # 5 Plaintiff Exhibit 3, # 6 Plaintiff SEALED Exhibit 4) (ag). (Entered: 02/15/2024) (Plaintiff Exhibit 3) (2) |
| Feb 8, 2024 | 698 | ORDER DENYING DEFENDANTS' EXPEDITED MOTION FOR ENTRY OF A SCHEDULING ORDER (ECF NO. 691 ). Signed by Chief District Judge Thomas S Kleeh on 2/8/2024. (dk) (Entered: 02/08/2024) (1) |
| Feb 6, 2024 | 697 | RESPONSE in Opposition re 691 MOTION DEFENDANTS EXPEDITED MOTION FOR ENTRY OF A SCHEDULING ORDER filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Ruby, Steven) (Entered: 02/06/2024) () (14) |
| Feb 6, 2024 | 697 | RESPONSE in Opposition re 691 MOTION DEFENDANTS EXPEDITED MOTION FOR ENTRY OF A SCHEDULING ORDER filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Ruby, Steven) (Entered: 02/06/2024) (Exhibit A) (2) |
| Feb 5, 2024 | 696 | ORDER GRANTING MOTION 695 TO CONTINUE HEARING. The hearing currently set for February 8, 2024, is CANCELLED. The hearing is RESET for February 15, 2024, at 10:00 a.m. in the Wheeling Magistrate Judge Courtroom, 4thFloor, before Magistrate Judge James P. Mazzone. Signed by Magistrate Judge James P. Mazzone on 2/5/2024. (dk) (Entered: 02/05/2024) (1) |
| Feb 1, 2024 | 694 | ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE granting 671 Motion of Rochelle Krawetz for Leave to Appear Pro Hac Vice; granting 672 Motion of Jennalee Beazley for Leave to Appear Pro Hac Vice. Signed by Chief District Judge Thomas S Kleeh on 2/1/2024. (dk) (Entered: 02/01/2024) (1) |
| Feb 1, 2024 | 695 | MOTION to Continue Hearing on Defendants Motion to Enforce the Protective Order and for Sanctions Related to Plaintiffs Protective Order Violations by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 02/01/2024) (4) |
| Jan 31, 2024 | 692 | REDACTED MEMORANDUM OPINION AND ORDER FOLLOWING BENCH TRIAL. Signed by Chief District Judge Thomas S Kleeh on 12/27/2023. (per Chambers (RR), document is not to be sealed) (dk) (Entered: 01/31/2024) (313) |
| Jan 31, 2024 | 693 | ORDER. Regeneron is DIRECTED to submit a response to Defendants' Expedited Motion for Entry of a Scheduling Order 691 on or before February 6, 2024. Signed by Chief District Judge Thomas S Kleeh on 01/31/2024. (snc) (Entered: 01/31/2024) (1) |
| Jan 30, 2024 | 684 | ORDER OF REFERRAL. Signed by Chief District Judge Thomas S Kleeh on 1/30/2024. (Copy to MJ Mazzone) (dk) (Entered: 01/30/2024) (1) |
| Jan 30, 2024 | 685 | ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/30/2024. (dk) (Entered: 01/30/2024) (1) |
| Jan 30, 2024 | 686 | ORDER. The motion is DENIED AS MOOT (ECF No. 605 ). Signed by Chief District Judge Thomas S Kleeh on 1/30/2024. (dk) (Entered: 01/30/2024) (1) |
| Jan 30, 2024 | 687 | USCA for the Federal Circuit NOTICE OF APPELLATE CASE OPENING re 676 Notice of Appeal filed by Regeneron Pharmaceuticals, Inc. USCA for the Federal Circuit Case Number: 2024-1402. (dk) (Entered: 01/30/2024) (4) |
| Jan 30, 2024 | 688 | USCA for the Federal Circuit NOTICE OF APPELLATE CASE OPENING re 677 Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. USCA for the Federal Circuit Case Number: 2024-1405. (dk) (Entered: 01/30/2024) (4) |
| Jan 30, 2024 | 689 | ORDER SETTING HEARING. Oral Argument/Evidentiary Hearing re 658 MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFF'S PROTECTIVE ORDER VIOLATIONS set for 2/8/2024 10:00 AM in Wheeling Magistrate Judge Courtroom, 4th Floor before Magistrate Judge James P. Mazzone. Signed by Magistrate Judge James P. Mazzone on 1/30/2024. (dk) (Entered: 01/30/2024) (1) |
| Jan 30, 2024 | 690 | Pro Hac Vice Filing fees received for Rhochelle Krawetz and Jennalee Beazler: $ 400, receipt number 100003821. (dk) (Entered: 01/30/2024) (0) |
| Jan 30, 2024 | 691 | MOTION DEFENDANTS EXPEDITED MOTION FOR ENTRY OF A SCHEDULING ORDER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 01/30/2024) () (13) |
| Jan 30, 2024 | 691 | MOTION DEFENDANTS EXPEDITED MOTION FOR ENTRY OF A SCHEDULING ORDER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 01/30/2024) (Proposed Order) (2) |
| Jan 29, 2024 | 680 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 676 Notice of Appeal by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Notice of Appeal, # 2 Certified WVN Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) () (1) |
| Jan 29, 2024 | 681 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 677 Notice of Appeal by Biocon Biologics, Inc. (Attachments: # 1 Notice of Appeal, # 2 WVN Certified Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) () (1) |
| Jan 29, 2024 | 682 | ORDER GRANTING MOTION TO RE-SEAL (ECF. NO. [660-1]). Signed by Chief District Judge Thomas S Kleeh on 1/29/2024. (dk) (Entered: 01/29/2024) (1) |
| Jan 29, 2024 | 683 | ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/29/2024. (dk) (Entered: 01/29/2024) (2) |
| Jan 29, 2024 | 681 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 677 Notice of Appeal by Biocon Biologics, Inc. (Attachments: # 1 Notice of Appeal, # 2 WVN Certified Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (Notice of Appeal) (3) |
| Jan 29, 2024 | 681 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 677 Notice of Appeal by Biocon Biologics, Inc. (Attachments: # 1 Notice of Appeal, # 2 WVN Certified Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (WVN Certified Docket Sheet) (30) |
| Jan 29, 2024 | 681 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 677 Notice of Appeal by Biocon Biologics, Inc. (Attachments: # 1 Notice of Appeal, # 2 WVN Certified Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (WVN Attorney List) (21) |
| Jan 29, 2024 | 681 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 677 Notice of Appeal by Biocon Biologics, Inc. (Attachments: # 1 Notice of Appeal, # 2 WVN Certified Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (WVN Clerk's Judgment) (1) |
| Jan 29, 2024 | 680 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 676 Notice of Appeal by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Notice of Appeal, # 2 Certified WVN Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (Notice of Appeal) (5) |
| Jan 29, 2024 | 680 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 676 Notice of Appeal by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Notice of Appeal, # 2 Certified WVN Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (Certified WVN Docket Sheet) (30) |
| Jan 29, 2024 | 680 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 676 Notice of Appeal by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Notice of Appeal, # 2 Certified WVN Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (WVN Attorney List) (21) |
| Jan 29, 2024 | 680 | Transmission of Notice of Appeal and Docket Sheet to United States Federal Circuit re 676 Notice of Appeal by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Notice of Appeal, # 2 Certified WVN Docket Sheet, # 3 WVN Attorney List, # 4 WVN Clerk's Judgment) (dk) (Additional attachment(s) added on 1/29/2024: # 5 Memorandum Opinion and Order - Sealed) (dk). (Entered: 01/29/2024) (WVN Clerk's Judgment) (1) |
| Jan 26, 2024 | 677 | Notice of Appeal* (1) |
| Jan 26, 2024 | 676 | Notice of Appeal* (1) |
| Jan 26, 2024 | 678 | MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 01/26/2024) (3) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) () (10) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Affidavit Decl. of Jake Rittahmel) (4) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. A) (2) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. B) (2) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. C) (2) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. D) (30) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. E) (30) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. F) (30) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. G) (30) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. H) (9) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. I) (30) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. J) (6) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. K) (5) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. L) (14) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. M) (4) |
| Jan 26, 2024 | 679 | MEMORANDUM DEFENDANTS MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. re 678 MOTION for Summary Judgment DEFENDANTS MOTION FOR SUMMARY JUDGMENT ON REGENERON COUNTS 7, 9, AND 11 FOR 35 U.S.C. § 253(b) STATUTORY DISCLAIMER . (Attachments: # 1 Affidavit Decl. of Jake Rittahmel, # 2 Exhibit Ex. A, # 3 Exhibit Ex. B, # 4 Exhibit Ex. C, # 5 Exhibit Ex. D, # 6 Exhibit Ex. E, # 7 Exhibit Ex. F, # 8 Exhibit Ex. G, # 9 Exhibit Ex. H, # 10 Exhibit Ex. I, # 11 Exhibit Ex. J, # 12 Exhibit Ex. K, # 13 Exhibit Ex. L, # 14 Exhibit Ex. M, # 15 Exhibit Ex. N)(Copland, Gordon) (Entered: 01/26/2024) (Exhibit Ex. N) (7) |
| Jan 25, 2024 | 675 | Joint MOTION JOINT MOTION REGARDING UNSEALING OF CERTAIN DOCKET ENTRIES by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 01/25/2024) () (5) |
| Jan 25, 2024 | 675 | Joint MOTION JOINT MOTION REGARDING UNSEALING OF CERTAIN DOCKET ENTRIES by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 01/25/2024) (Proposed Order) (2) |
| Jan 19, 2024 | 674 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Fifth Requests for Production of Documents to Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. (Pogue, David) (Entered: 01/19/2024) (2) |
| Jan 11, 2024 | 671 | MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2) |
| Jan 11, 2024 | 672 | MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2) |
| Jan 11, 2024 | 673 | NOTICE by Regeneron Pharmaceuticals, Inc. of Filing of Motion for Transfer of Action to the Northern District of West Virginia Pursuant to 28 U.S.C. 1407 for Coordinated Pretrial Proceedings (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/11/2024) () (5) |
| Jan 11, 2024 | 671 | MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6) |
| Jan 11, 2024 | 671 | MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1) |
| Jan 11, 2024 | 671 | MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2) |
| Jan 11, 2024 | 671 | MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1) |
| Jan 11, 2024 | 672 | MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6) |
| Jan 11, 2024 | 672 | MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1) |
| Jan 11, 2024 | 672 | MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2) |
| Jan 11, 2024 | 672 | MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1) |
| Jan 11, 2024 | 673 | NOTICE by Regeneron Pharmaceuticals, Inc. of Filing of Motion for Transfer of Action to the Northern District of West Virginia Pursuant to 28 U.S.C. 1407 for Coordinated Pretrial Proceedings (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/11/2024) (Exhibit A) (7) |
| Jan 10, 2024 | 670 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 01/10/2024. (Copy emailed to counsel) (snc) (Entered: 01/10/2024) (0) |
| Jan 3, 2024 | 669 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/3/2024. Copy to Counsel.(cmd) (Entered: 01/03/2024) (0) |
| Dec 29, 2023 | 667 | ORDER GRANTING MOTION TO WITHDRAW (ECF NO. 648 ). Attorney Nicholas Jordan terminated. Signed by Chief District Judge Thomas S Kleeh on 12/29/2023. (dk) (Entered: 12/29/2023) (1) |
| Dec 29, 2023 | 668 | DEFENDANTS REPLY TO REGENERONS OPPOSITION TO DEFENDANTS MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFFS PROTECTIVE ORDER VIOLATIONS by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Defendants' Reply, # 2 Exhibit P, # 3 Exhibit Q, # 4 Exhibit R, # 5 Exhibit S, # 6 Exhibit T, # 7 Exhibit U, # 8 Exhibit V, # 9 Exhibit W, # 10 Exhibit X)(O'Brien, William) Modified on 1/3/2024 (cmd). (Entered: 12/29/2023) (0) |
| Dec 27, 2023 | 662 | ORDER MEMORIALIZING RULINGS. Signed by Chief District Judge Thomas S Kleeh on 12/27/2023. (dk) (Entered: 12/27/2023) (1) |
| Dec 27, 2023 | 663 | ORDER DENYING AS MOOT DEFENDANTS' MOTION TO EXCLUDE (ECF NO. 547 ). Signed by Chief District Judge Thomas S Kleeh on 12/27/2023. (dk) (Entered: 12/27/2023) (1) |
| Dec 27, 2023 | 664 | SEALED MEMORANDUM OPINION AND ORDER FOLLOWING BENCH TRIAL. Signed by Chief District Judge Thomas S Kleeh on 12/27/2023. (Emailed to Counsel of Record) (dk) (Entered: 12/27/2023) (0) |
| Dec 27, 2023 | 665 | CLERK'S JUDGMENT. Signed by Clerk of Court on 12/27/2023. (dk) (Entered: 12/27/2023) (1) |
| Dec 27, 2023 | 666 | ORDER DENYING AS MOOT DEFENDANTS' ORAL MOTION TO RENEW MOTION IN LIMINE NO. 5 (ECF NO. 550 ). Signed by Chief District Judge Thomas S Kleeh on 12/27/2023. (dk) (Entered: 12/27/2023) (1) |
| Dec 22, 2023 | 661 | REGENERONS MEMORANDUM IN OPPOSITION TO DEFENDANTS MOTION FOR SANCTIONS RELATED TO PROTECTIVE ORDER by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Memorandum in Opposition to Defendants' Motion for Sanctions Related to Protective Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6, # 9 Exhibit 7, # 10 Exhibit 8, # 11 Exhibit 9, # 12 Exhibit 10, # 13 Exhibit 11, # 14 Exhibit 12, # 15 Exhibit 13, # 16 Exhibit 14, # 17 Exhibit 15, # 18 Exhibit 16, # 19 Exhibit 17, # 20 Exhibit 18, # 21 Exhibit 19, # 22 Exhibit 20, # 23 Exhibit 21, # 24 Exhibit 22, # 25 Exhibit 23, # 26 Exhibit 24, # 27 Exhibit 25, # 28 Exhibit 26, # 29 Exhibit 27, # 30 Exhibit 28, # 31 Exhibit 29, # 32 Exhibit 30, # 33 Exhibit 31, # 34 Exhibit 32, # 35 Exhibit 33, # 36 Exhibit 34, # 37 Exhibit 35, # 38 Exhibit 36, # 39 Exhibit 37, # 40 Exhibit 38, # 41 Exhibit 39, # 42 Exhibit 40, # 43 Exhibit 41, # 44 Exhibit 42, # 45 Exhibit 43, # 46 Exhibit 44, # 47 Exhibit 45, # 48 Exhibit 46, # 49 Exhibit 47, # 50 Exhibit 48, # 51 Exhibit 49, # 52 Exhibit 50, # 53 Exhibit 51, # 54 Exhibit 52, # 55 Exhibit 53, # 56 Exhibit 54, # 57 Exhibit 55, # 58 Exhibit 56, # 59 Exhibit 57)(Pogue, David) Modified on 1/3/2024 (cmd). (Entered: 12/22/2023) (0) |
| Dec 21, 2023 | 660 | DEFENDANTS EXPEDITED MOTION TO RE-SEAL CERTAIN DOCKET ENTRIES AND FILE REDACED COPIES OF SAME by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Motion to Re-Seal, # 2 Exhibit A, # 3 Exhibit B, # 4 Exhibit C, # 5 Exhibit D, # 6 Exhibit E, # 7 Exhibit F, # 8 Exhibit G)(O'Brien, William) Modified on 1/3/2024 (cmd). (Entered: 12/21/2023) (0) |
| Dec 11, 2023 | 657 | NOTICE OF DOCKET CORRECTION re 640 Order. ERROR: Documents listed in Order for unsealing were not properly unsealed. CORRECTION: DQA properly unsealed all documents listed in the Order. (cmd) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 658 | MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFF'S PROTECTIVE ORDER VIOLATIONS by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 12/11/2023) (3) |
| Dec 11, 2023 | 659 | MEMORANDUM IN SUPPORT OF DEFENDANTS MOTION TO ENFORCE THE PROTECTIVE ORDER AND FOR SANCTIONS RELATED TO PLAINTIFFS PROTECTIVE ORDER VIOLATIONS by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Memo, # 2 Exhibit A, # 3 Exhibit B, # 4 Exhibit C, # 5 Exhibit D, # 6 Exhibit E, # 7 Exhibit F, # 8 Exhibit G, # 9 Exhibit H, # 10 Exhibit I, # 11 Exhibit J, # 12 Exhibit K, # 13 Exhibit L, # 14 Exhibit M, # 15 Exhibit N, # 16 Exhibit O)(O'Brien, William) Modified on 1/3/2024 (cmd). (Entered: 12/11/2023) (0) |
| Dec 7, 2023 | 655 | REDACTION Motion to Convene Status Conference [Dkt. No. 649-2] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 12/07/2023) (4) |
| Dec 7, 2023 | 656 | REDACTION Defendants' Response to Motion to Convene Status Conference [Dkt. No. 654] by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 12/07/2023) (2) |
| Dec 6, 2023 | 653 | ORDER granting 652 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/6/2023. (Emailed to Counsel) (dk) (Entered: 12/06/2023) (0) |
| Nov 28, 2023 | 650 | ORDER granting 649 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 11/28/2023. (Emailed to Counsel of Record) (dk) (Entered: 11/28/2023) (0) |
| Nov 2, 2023 | 648 | MOTION to Withdraw as Attorney - NICHOLAS JORDAN'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 11/02/2023) (3) |
| Oct 23, 2023 | 645 | ORDER Granting 642 Motion for Leave to Appear Pro Hac Vice for Anish Desai filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 10/23/2023. (mas) (Entered: 10/23/2023) (1) |
| Oct 23, 2023 | 646 | ORDER Granting 641 Motion for Leave to Appear Pro Hac Vice of Elizabeth S. Weiswasser filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 10/23/2023. (mas) (Entered: 10/23/2023) (1) |
| Oct 23, 2023 | 647 | ORDER Granting 643 Motion for Leave to Appear Pro Hac Vice of Christopher M. Pepe filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 10/23/2023. (mas) (Entered: 10/23/2023) (1) |
| Oct 17, 2023 | 644 | Filing fee: $ 600.00, receipt number 100003751 Re: Pro Hac Vice payments received for Elizabeth S. Weiswasser, Anish Desai and Christopher M. Pepe. (mas) (Entered: 10/17/2023) (0) |
| Oct 16, 2023 | 641 | MOTION for Leave to Appear for Pro Hac Vice Admission of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) () (2) |
| Oct 16, 2023 | 642 | MOTION for Leave to Appear of Pro Hac Vice Admission for Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) () (2) |
| Oct 16, 2023 | 643 | MOTION for Leave to Appear for Pro Hac Vice Admission for Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) () (2) |
| Oct 16, 2023 | 642 | MOTION for Leave to Appear of Pro Hac Vice Admission for Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) (Attachment WVSB Receipt) (1) |
| Oct 16, 2023 | 642 | MOTION for Leave to Appear of Pro Hac Vice Admission for Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) (Proposed Order) (1) |
| Oct 16, 2023 | 641 | MOTION for Leave to Appear for Pro Hac Vice Admission of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) (Attachment WVSB Receipt) (2) |
| Oct 16, 2023 | 641 | MOTION for Leave to Appear for Pro Hac Vice Admission of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) (Proposed Order) (1) |
| Oct 16, 2023 | 643 | MOTION for Leave to Appear for Pro Hac Vice Admission for Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) (Attachment WVSB Receipt) (2) |
| Oct 16, 2023 | 643 | MOTION for Leave to Appear for Pro Hac Vice Admission for Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 10/16/2023) (Proposed Order) (1) |
| Oct 6, 2023 | 640 | ORDER granting 639 MOTION Regarding Unsealing of Certain Docket Entries. Signed by Chief District Judge Thomas S Kleeh on 10/6/2023. (mas) (Entered: 10/06/2023) (2) |
| Sep 29, 2023 | 639 | Joint MOTION Regarding Unsealing of Certain Docket Entries by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 09/29/2023) () (3) |
| Sep 29, 2023 | 639 | Joint MOTION Regarding Unsealing of Certain Docket Entries by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 09/29/2023) (Proposed Order) (2) |
| Sep 21, 2023 | 638 | ORDER granting 637 Joint MOTION. Signed by Chief District Judge Thomas S Kleeh on 9/21/2023. (Copy of docket sheet emailed to counsel) (mas) (Entered: 09/21/2023) (1) |
| Sep 13, 2023 | 637 | Joint MOTION Release of Complete Docket Sheet re 609 Response, 608 Notice (Other) by AMGEN USA, INC., BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Tinney, John) (Entered: 09/13/2023) () (4) |
| Sep 13, 2023 | 637 | Joint MOTION Release of Complete Docket Sheet re 609 Response, 608 Notice (Other) by AMGEN USA, INC., BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Tinney, John) (Entered: 09/13/2023) (Proposed Order) (1) |
| Sep 12, 2023 | 636 | STATUS REPORT -Joint Status Report Regarding Unsealing and Redaction of Filings in Response to Celltrion, Inc.s Motion to Intervene by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 09/12/2023) (3) |
| Sep 8, 2023 | 635 | REDACTION Exhibit 22 to Def. Motion for Summary Judgment - No. 432-24 by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Supplement Part 2 of Exh 22 - pages 148 to 269, # 2 Supplement Part 3 of Exh 22 - pages 270 to 337)(Copland, Gordon) (Entered: 09/08/2023) () (30) |
| Sep 8, 2023 | 635 | REDACTION Exhibit 22 to Def. Motion for Summary Judgment - No. 432-24 by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Supplement Part 2 of Exh 22 - pages 148 to 269, # 2 Supplement Part 3 of Exh 22 - pages 270 to 337)(Copland, Gordon) (Entered: 09/08/2023) (Supplement Part 2 of Exh 22 - pages 148 to 269) (30) |
| Sep 8, 2023 | 635 | REDACTION Exhibit 22 to Def. Motion for Summary Judgment - No. 432-24 by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Supplement Part 2 of Exh 22 - pages 148 to 269, # 2 Supplement Part 3 of Exh 22 - pages 270 to 337)(Copland, Gordon) (Entered: 09/08/2023) (Supplement Part 3 of Exh 22 - pages 270 to 337) (30) |
| Sep 1, 2023 | 610 | [REDACTED] Defendant Mylan Pharmaceuticals Inc. Opening Claim Construction Brief - Dkt. No. 122 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 611 | [REDACTED] Defendant Mylan Pharmaceuticals Inc.'s Responsive Claim Construction Brief - Dkt. No. 173-1 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 612 | [REDACTED] Defendant Mylan Pharmaceuticals Inc.'s Alternative Submission Regarding Plaintiff's Unauthorized "Observations Concerning Post-Briefing Depositions" - Dkt. No. 264-1 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (11) |
| Sep 1, 2023 | 613 | [REDACTED] Exhibit D - Dkt. No. 264-2 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 614 | [REDACTED] Exhibit E - Dkt. No. 264-3 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 615 | [REDACTED] Defendant Mylan Pharmaceuticals Inc.'s Memorandum in Support of Its Motion for Summary Judgment or Partial Summary Judgment on U.S. Patent Nos. 11,104,715 (Process Patent); 11,084,865 (Formulation Patent); and 10,888,601 & 11,253,572 (Dosing Patents) - Dkt. No. 432 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 616 | [REDACTED] Defendant Mylan Pharmaceuticals Inc.'s L.R. Civ. P. 7.02 Statement of Uncontroverted Facts for Purposes of Mylan's Motion for Summary Judgment or Partial Summary Judgment on U.S. Patent Nos. 11,104,715 (Process Patent); 11,084,865 (Formulation Patent); and 10,888,601 & 11,253,572 (Dosing Patents) - Dkt. No. 432-1 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 617 | [REDACTED] Exhibit 1 - Dkt. No. 432-3 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 618 | [REDACTED] Exhibit 2 - Dkt. No. 432-4 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 619 | [REDACTED] Exhibit 5 - Dkt. No. 432-7 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 620 | [REDACTED] Exhibit 12 - Dkt. No. 432-14 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (21) |
| Sep 1, 2023 | 621 | [REDACTED] Exhibit 14 - Dkt. No. 432-16 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 622 | Exhibit 15 - Dkt. No. 432-17 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 623 | [REDACTED] Exhibit 16 - Dkt. No. 432-18 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (15) |
| Sep 1, 2023 | 624 | [REDACTED] Exhibit 24 - Dkt. No. 432-26 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 625 | [REDACTED] Exhibit 25 - Dkt. No. 432-27 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 626 | [REDACTED] Exhibit 27 - Dkt. No. 432-29 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 627 | [REDACTED] Exhibits H, J, K, L, O, T, and Y - Dkt. Nos. 441-11, 13, 14, 15, 18, 23, and 28, respectively ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 628 | [REDACTED] Defendant Mylan Pharmaceuticals Inc.'s Reply Memorandum in Support of Mylan's Motion for Summary Judgment, Declaration of L. Scott Beall, Exhibits 28, 29, 30, 31, 32, 33, 35, 36, and 41 respectively - Dkt. No. 432 ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 629 | REDACTION Ex. B to Regeneron's Observations Concerning Post-Briefing Depositions of Mylan's Claim Construction Experts [Dkt. No. 226-4] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 09/01/2023) (3) |
| Sep 1, 2023 | 630 | REDACTION Regeneron's Opposition to Mylan's Motion for Summary Judgment [Dkt. No. 440-2] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 631 | REDACTION Plaintiff Regeneron Pharmaceuticals, Inc.'s Response to Mylan's Statement of Uncontroverted Facts [Dkt. No. 440-3] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 632 | REDACTION Regeneron's Opposition to Mylan's Motion for Summary Judgment, with Exhibits [Dkt. Nos. 443, 443-1, 443-2, 443-3, 443-4, 443-5, 443-6, 443-7, 443-8, 443-9, 443-10, 443-11, 443-12, 443-13, 443-14, 443-15, 443-16, 443-17, 443-18, 443-19] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 09/01/2023) (30) |
| Sep 1, 2023 | 633 | REDACTION Ex. 15 to Regeneron's Reply in Support of Motion for Summary Judgment [Dkt. No. 448-5] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 09/01/2023) (4) |
| Sep 1, 2023 | 634 | REDACTION Ex. 15 to Regeneron's Reply in Support of Motion for Summary Judgment [Dkt. No. 463-3] by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 09/01/2023) (4) |
| Aug 29, 2023 | 609 | RESPONSE by AMGEN USA, INC. to 608 Notice (Other). (Tinney, John) (Entered: 08/29/2023) (4) |
| Aug 25, 2023 | 608 | NOTICE by Regeneron Pharmaceuticals, Inc. Joint Notice Regarding Unsealing and Redaction of Filings in Response to Amgen USA, Inc.'s Motion to Intervene (Pogue, David) (Entered: 08/25/2023) (4) |
| Aug 24, 2023 | 606 | RESPONSE to Motion re 605 MOTION to Intervene filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 08/24/2023) (4) |
| Aug 24, 2023 | 607 | RESPONSE to Motion re 605 MOTION to Intervene DEFENDANTS RESPONSE TO MOTION TO INTERVENE (DKT. NO. 605) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 08/24/2023) (3) |
| Aug 10, 2023 | 605 | MOTION to Intervene by Celltrion, Inc.. (Attachments: # 1 Attachment Memorandum)(Davis, Laura) (Entered: 08/10/2023) () (3) |
| Aug 10, 2023 | 605 | MOTION to Intervene by Celltrion, Inc.. (Attachments: # 1 Attachment Memorandum)(Davis, Laura) (Entered: 08/10/2023) (Attachment Memorandum) (15) |
| Aug 9, 2023 | 604 | TRANSCRIPT PURCHASE ORDER for proceedings held on 8/3/2023 before Judge Kleeh. (ck) (Entered: 08/09/2023) (1) |
| Aug 4, 2023 | 599 | TRANSCRIPT of closing arguments held on 8/3/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 8/25/2023. Redacted Transcript Deadline set for 9/5/2023. Release of Transcript Restriction set for 11/2/2023. (ck) (Entered: 08/04/2023) (0) |
| Aug 4, 2023 | 600 | *SEALED* TRANSCRIPT of Sealed Hearing held on 8/3/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 08/04/2023) (0) |
| Aug 4, 2023 | 601 | TRANSCRIPT PURCHASE ORDER for proceedings held on 6/13 and 6/22/2023 before Judge Kleeh. (ck) (Entered: 08/04/2023) (1) |
| Aug 3, 2023 | 598 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Closing arguments held on 8/3/2023. Bench Trial completed on 8/3/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 08/03/2023) (0) |
| Aug 1, 2023 | 596 | ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. Granting 594 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 8/1/2023. (copy to counsel) (hrc) (Entered: 08/01/2023) (0) |
| Jul 31, 2023 | 595 | NOTICE. Signed by Chief District Judge Thomas S Kleeh on 7/31/2023. (hrc) (Entered: 07/31/2023) (1) |
| Jul 28, 2023 | 588 | ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. Granting 584 , 585 , 586 and 587 Motions. ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 7/28/2023. (copy to counsel)(hrc) (Entered: 07/28/2023) (0) |
| Jul 28, 2023 | 593 | Defendants' Reply Post Trial Brief - Issues Where Defendants Bear the Burden of Proof ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1)(O'Brien, William) (Entered: 07/28/2023) () (19) |
| Jul 28, 2023 | 593 | Defendants' Reply Post Trial Brief - Issues Where Defendants Bear the Burden of Proof ( Other Document ) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1)(O'Brien, William) (Entered: 07/28/2023) (Exhibit 1) (30) |
| Jul 18, 2023 | 579 | Joint MOTION for Extension of Time to File Responsive briefs and Proposed findings, without altering reply deadline by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 07/18/2023) () (3) |
| Jul 18, 2023 | 580 | ORDER GRANTING MOTION TO SEAL [ECF NO. 577 ]. Signed by Chief District Judge Thomas S Kleeh on 7/18/2023. (hrc) (Entered: 07/18/2023) (2) |
| Jul 18, 2023 | 582 | ORDER: Granting 579 Motion for Extension of Time to File. Signed by Chief District Judge Thomas S Kleeh on 7/18/2023. (hrc) (Entered: 07/18/2023) (1) |
| Jul 18, 2023 | 583 | NOTICE of Appearance by Michael W. Carey on behalf of Regeneron Pharmaceuticals, Inc. (Carey, Michael) (Entered: 07/18/2023) (2) |
| Jul 18, 2023 | 579 | Joint MOTION for Extension of Time to File Responsive briefs and Proposed findings, without altering reply deadline by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 07/18/2023) (Proposed Order) (1) |
| Jul 12, 2023 | 578 | ORDER CHANGING LOCATION OF CLOSING ARGUMENTS. The Court RESCHEDULES closing arguments to occur in person at the West Virginia University College of Law, in the Lugar Courtroom. The time and date of the arguments remain unchanged. Signed by Chief District Judge Thomas S Kleeh on 7/12/2023. (hrc) (Entered: 07/12/2023) (1) |
| Jul 7, 2023 | 576 | Other Document Defendants Opening Post Trial Brief Issues Where Defendants Bear The Burden of Proof filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Appendix Appendix Providing Exhibit Reference List)(Copland, Gordon) (Entered: 07/07/2023) () (30) |
| Jul 7, 2023 | 577 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Attachment Regeneron's Opening Post-Trial Brief Addressing Infringement of the Asserted Patents)(Pogue, David) (Entered: 07/07/2023) () (4) |
| Jul 7, 2023 | 576 | Other Document Defendants Opening Post Trial Brief Issues Where Defendants Bear The Burden of Proof filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Appendix Appendix Providing Exhibit Reference List)(Copland, Gordon) (Entered: 07/07/2023) (Appendix Appendix Providing Exhibit Reference List) (5) |
| Jul 7, 2023 | 577 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Attachment Regeneron's Opening Post-Trial Brief Addressing Infringement of the Asserted Patents)(Pogue, David) (Entered: 07/07/2023) (Attachment Memorandum In Support) (6) |
| Jul 6, 2023 | 575 | CLERK'S TRIAL WITNESS AND EXHIBIT LIST for Bench Trial held 6/12/23 - 6/23/23. (dk) (Entered: 07/06/2023) (0) |
| Jun 28, 2023 | 574 | TRANSCRIPT PURCHASE ORDER for proceedings held on 6/12/2023 to 6/23/2023 before Judge Kleeh. (ck) (Entered: 06/28/2023) (1) |
| Jun 27, 2023 | 571 | TRANSCRIPT of bench trial, Volume 4, held on 6/15/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/18/2023. Redacted Transcript Deadline set for 7/28/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/27/2023) (246) |
| Jun 27, 2023 | 572 | TRANSCRIPT PURCHASE ORDER by Regeneron Pharmaceuticals, Inc. for proceedings held on 6/12 to 6/23/2023 before Judge Kleeh. (ck) (Entered: 06/27/2023) (1) |
| Jun 27, 2023 | 573 | TRANSCRIPT PURCHASE ORDER by Mylan Pharmaceuticals Inc. for proceedings held on 6/12/2023 to 6/23/2023 before Judge Kleeh. (ck) (Entered: 06/27/2023) (1) |
| Jun 26, 2023 | 556 | Modified on 6/26/2023 - incorrect document filed, to be refiled by court reporter. (kac). (Main Document 556 replaced on 6/26/2023) (kac). (Entered: 06/26/2023) (1) |
| Jun 26, 2023 | 557 | *SEALED* TRANSCRIPT of Sealed Hearing held on 6/12/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 06/26/2023) (0) |
| Jun 26, 2023 | 558 | TRANSCRIPT of bench trial, Volume 1, held on 6/12/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (252) |
| Jun 26, 2023 | 559 | TRANSCRIPT of bench trial, Volume 2, held on 6/13/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (275) |
| Jun 26, 2023 | 560 | TRANSCRIPT of bench trial, Volume 3, held on 6/14/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (75) |
| Jun 26, 2023 | 561 | *SEALED* TRANSCRIPT of Sealed Hearing held on 6/14/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 06/26/2023) (0) |
| Jun 26, 2023 | 562 | Modified on 6/27/2023 - document removed, incorrect event used. (kac). (Entered: 06/26/2023) (1) |
| Jun 26, 2023 | 563 | TRANSCRIPT of bench trial, Volume 5, held on 6/16/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (236) |
| Jun 26, 2023 | 564 | TRANSCRIPT of bench trial, Volume 6, held on 6/20/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (243) |
| Jun 26, 2023 | 565 | *SEALED* TRANSCRIPT of Sealed Hearing held on 6/20/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 06/26/2023) (0) |
| Jun 26, 2023 | 566 | TRANSCRIPT of bench trial, Volume 7, held on 6/21/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (277) |
| Jun 26, 2023 | 567 | *SEALED* TRANSCRIPT of Sealed Hearing held on 6/21/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 06/26/2023) (0) |
| Jun 26, 2023 | 568 | TRANSCRIPT of bench trial, Volume 8, held on 6/22/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (246) |
| Jun 26, 2023 | 569 | TRANSCRIPT of bench trial, Volume 9, held on 6/23/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 7/17/2023. Redacted Transcript Deadline set for 7/27/2023. Release of Transcript Restriction set for 9/25/2023. (ck) (Entered: 06/26/2023) (161) |
| Jun 26, 2023 | 570 | *SEALED* TRANSCRIPT of Sealed Hearing held on 6/23/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968.. (ck) (Entered: 06/26/2023) (0) |
| Jun 23, 2023 | 555 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day Nine held on 6/23/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/23/2023) (0) |
| Jun 22, 2023 | 552 | STIPULATION Regarding Commercial Success by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 06/22/2023) (6) |
| Jun 22, 2023 | 553 | JOINT STIPULATION REGARDING COMMERCIAL SUCCESS. Signed by Chief District Judge Thomas S Kleeh on 6/22/2023. (hrc) (Entered: 06/22/2023) (5) |
| Jun 22, 2023 | 554 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day Eight held on 6/22/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/22/2023) (0) |
| Jun 21, 2023 | 546 | MOTION TO EXCLUDE REGENERON'S UNDISCLOSED AND UNCORROBORATED THEORIES OF CONCEPTION AND REDUCTION TO PRACTICE AND EXPERT TESTIMONY by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(O'Brien, William) (Entered: 06/21/2023) () (21) |
| Jun 21, 2023 | 547 | MOTION TO EXCLUDE EXPERT DEPOSITION TESTIMONY OF DRS. ALAN RYDER AND STEPHEN R. RUSSELL by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 06/21/2023) (10) |
| Jun 21, 2023 | 548 | ORAL MOTION FOR JUDGMENT PURSUANT TO RULE 52(c) by Regeneron Pharmaceuticals, Inc. (dk) (Entered: 06/21/2023) (0) |
| Jun 21, 2023 | 549 | ORAL ORDER deferring ruling on 548 Oral Motion for Judgment Pursuant to Rule 52(c) filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 6/21/2023. (dk) (Entered: 06/21/2023) (0) |
| Jun 21, 2023 | 550 | ORAL MOTION TO RENEW MOTION IN LIMINE NO. 5 by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (dk) (Entered: 06/21/2023) (0) |
| Jun 21, 2023 | 551 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day Seven held on 6/21/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/21/2023) (0) |
| Jun 21, 2023 | 546 | MOTION TO EXCLUDE REGENERON'S UNDISCLOSED AND UNCORROBORATED THEORIES OF CONCEPTION AND REDUCTION TO PRACTICE AND EXPERT TESTIMONY by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(O'Brien, William) (Entered: 06/21/2023) (Exhibit A) (9) |
| Jun 20, 2023 | 545 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day Six held on 6/20/2023. (Court Reporter Cindy Knecht) (dk) (Main Document 545 replaced to correct typographical error on 6/21/2023) (dk). (Entered: 06/20/2023) (0) |
| Jun 16, 2023 | 540 | Second MOTION to Exclude Undisclosed Expert Opinion by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 06/16/2023) (12) |
| Jun 16, 2023 | 541 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 539 ]. Signed by Chief District Judge Thomas S Kleeh on 6/16/2023. (jb) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 544 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day Five held on 6/16/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/16/2023) (0) |
| Jun 15, 2023 | 533 | RESPONSE in Opposition re 529 MOTION to Exclude Undisclosed Expert Opinion filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 06/15/2023) (12) |
| Jun 15, 2023 | 535 | RESPONSE in Opposition re 529 MOTION to Exclude Undisclosed Expert Opinion (CORRECTED from Dkt. No. 533)) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 06/15/2023) (13) |
| Jun 15, 2023 | 536 | RESPONSE in Opposition re 529 MOTION to Exclude Undisclosed Expert Opinion (FURTHER CORRECTED from Dkt. Nos. 535 and 533) filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 06/15/2023) (12) |
| Jun 15, 2023 | 537 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial held on 6/15/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | 538 | NOTICE by Regeneron Pharmaceuticals, Inc. of Designated Deposition Testimony (Attachments: # 1 Attachment Goyal deposition designations, # 2 Attachment Chang deposition designations, # 3 Attachment Smith deposition designations)(Ruby, Steven) (Entered: 06/15/2023) () (4) |
| Jun 15, 2023 | 538 | NOTICE by Regeneron Pharmaceuticals, Inc. of Designated Deposition Testimony (Attachments: # 1 Attachment Goyal deposition designations, # 2 Attachment Chang deposition designations, # 3 Attachment Smith deposition designations)(Ruby, Steven) (Entered: 06/15/2023) (Attachment Goyal deposition designations) (1) |
| Jun 15, 2023 | 538 | NOTICE by Regeneron Pharmaceuticals, Inc. of Designated Deposition Testimony (Attachments: # 1 Attachment Goyal deposition designations, # 2 Attachment Chang deposition designations, # 3 Attachment Smith deposition designations)(Ruby, Steven) (Entered: 06/15/2023) (Attachment Chang deposition designations) (1) |
| Jun 15, 2023 | 538 | NOTICE by Regeneron Pharmaceuticals, Inc. of Designated Deposition Testimony (Attachments: # 1 Attachment Goyal deposition designations, # 2 Attachment Chang deposition designations, # 3 Attachment Smith deposition designations)(Ruby, Steven) (Entered: 06/15/2023) (Attachment Smith deposition designations) (12) |
| Jun 14, 2023 | 529 | MOTION to Exclude Undisclosed Expert Opinion by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 06/14/2023) (10) |
| Jun 14, 2023 | 530 | DEFENDANTS' ORAL MOTION FOR JUDGMENT PURSUANT TO RULE 52(c) by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (dk) (Entered: 06/14/2023) (0) |
| Jun 14, 2023 | 531 | ORAL ORDER denying Defendants' Oral Motion for Judgment Pursuant to Rule 52(c) by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 6/14/2023. (dk) (Entered: 06/14/2023) (0) |
| Jun 14, 2023 | 532 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial held on 6/14/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/14/2023) (0) |
| Jun 14, 2023 | 534 | MOTION/LETTER TO EXCLUDE TESTIMONY OF KAREN CHU by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Attachments: # 1 Exhibit 1 - Chu Combined Designations, # 2 Exhibit 2 - Thompson v Kawasaki Heavy Industries, Ltd., # 3 Exhibit 3 - Karen Chu Deposition Topics (DTX 0202) (Filed as Motion per Chambers) (dk) (Entered: 06/15/2023) () (14) |
| Jun 14, 2023 | 534 | MOTION/LETTER TO EXCLUDE TESTIMONY OF KAREN CHU by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Attachments: # 1 Exhibit 1 - Chu Combined Designations, # 2 Exhibit 2 - Thompson v Kawasaki Heavy Industries, Ltd., # 3 Exhibit 3 - Karen Chu Deposition Topics (DTX 0202) (Filed as Motion per Chambers) (dk) (Entered: 06/15/2023) (Exhibit 1 - Chu Combined Designations) (30) |
| Jun 14, 2023 | 534 | MOTION/LETTER TO EXCLUDE TESTIMONY OF KAREN CHU by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Attachments: # 1 Exhibit 1 - Chu Combined Designations, # 2 Exhibit 2 - Thompson v Kawasaki Heavy Industries, Ltd., # 3 Exhibit 3 - Karen Chu Deposition Topics (DTX 0202) (Filed as Motion per Chambers) (dk) (Entered: 06/15/2023) (Exhibit 2 - Thompson v Kawasaki Heavy Industries, Ltd.) (20) |
| Jun 14, 2023 | 534 | MOTION/LETTER TO EXCLUDE TESTIMONY OF KAREN CHU by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. (Attachments: # 1 Exhibit 1 - Chu Combined Designations, # 2 Exhibit 2 - Thompson v Kawasaki Heavy Industries, Ltd., # 3 Exhibit 3 - Karen Chu Deposition Topics (DTX 0202) (Filed as Motion per Chambers) (dk) (Entered: 06/15/2023) (Exhibit 3 - Karen Chu Deposition Topics (DTX 0202)) (1) |
| Jun 13, 2023 | 528 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day Two held on 6/13/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/13/2023) (0) |
| Jun 12, 2023 | 526 | MEMORANDUM of Law In Support of Motion to Close Limited Portions of Trial Proceedings by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc. . (O'Brien, William) (Entered: 06/12/2023) (6) |
| Jun 12, 2023 | 527 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Bench Trial - Day One held on 6/12/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 06/12/2023) (0) |
| Jun 6, 2023 | 524 | MEMORANDUM OPINION AND ORDER DENYING MYLAN'S SECOND MOTION TO AMEND [ECF NO. 505 ] AND GRANTING REGENERON'S MOTION FOR JUDGMENT ON THE PLEADINGS [ECF NO. 175 ]. Signed by Chief District Judge Thomas S Kleeh on 6/6/2023. (hrc) (Entered: 06/06/2023) (4) |
| Jun 6, 2023 | 525 | ORDER DENYING MOTIONS FOR SUMMARY JUDGMENT [ECF NO. 428 , 429 ] AND RELATED MOTIONS [ECF NOS. 439 , 483 , 484 ]. Signed by Chief District Judge Thomas S Kleeh on 6/6/2023. (hrc) (Entered: 06/06/2023) (2) |
| Jun 5, 2023 | 522 | ORDER GRANTING JOINT MOTION TO PERMIT ENTRY TO THE COURTHOUSE WITH ELECTRONIC EQUIPMENT. Signed by Chief District Judge Thomas S Kleeh on 6/5/2023. (hrc) (Entered: 06/05/2023) (2) |
| Jun 5, 2023 | 523 | STIPULATION AND ORDER JOINING BIOCON BIOLOGICS INC. AS DEFENDANT. Signed by Chief District Judge Thomas S Kleeh on 6/5/2023. (hrc) (Entered: 06/05/2023) (8) |
| Jun 3, 2023 | 521 | Joint MOTION TO PERMIT ENTRY TO THE COURTHOUSE WITH ELECTRONIC EQUIPMENT by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 06/03/2023) () (3) |
| Jun 3, 2023 | 521 | Joint MOTION TO PERMIT ENTRY TO THE COURTHOUSE WITH ELECTRONIC EQUIPMENT by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 06/03/2023) (Proposed Order) (2) |
| Jun 2, 2023 | 517 | TRANSCRIPT of pretrial conference held on 5/30/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 6/23/2023. Redacted Transcript Deadline set for 7/3/2023. Release of Transcript Restriction set for 8/31/2023. (ck) (Entered: 06/02/2023) (87) |
| Jun 2, 2023 | 518 | TRANSCRIPT PURCHASE ORDER by Regeneron Pharmaceuticals, Inc. for proceedings held on 5/30/2023 before Judge Kleeh. (ck) (Entered: 06/02/2023) (1) |
| Jun 2, 2023 | 519 | TRANSCRIPT PURCHASE ORDER by Mylan Pharmaceuticals Inc. for proceedings held on 5/30/2023 before Judge Kleeh. (ck) (Entered: 06/02/2023) (1) |
| Jun 2, 2023 | 520 | STIPULATION STIPULATION AND ORDER JOINING BIOCON BIOLOGICS INC. AS DEFENDANT by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 06/02/2023) (8) |
| May 31, 2023 | 516 | ORDER. Granting 485 Motion to Intervene. Signed by Chief District Judge Thomas S Kleeh on 5/31/2023. (hrc) (Entered: 05/31/2023) (1) |
| May 30, 2023 | 511 | NOTICE by Regeneron Pharmaceuticals, Inc. of Mootness Regarding Regeneron's Motion to Preclude Testimony of Dr. Russell and Mylan's Contingent Cross Motion to Strike Testimony of Dr. Csaky. (Pogue, David) (Entered: 05/30/2023) (5) |
| May 30, 2023 | 512 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Pretrial Conference held on 5/30/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 513 | ORDER ADDRESSING MOTIONS IN LIMINE. 453 , 467 , 450 , 506 , 507 , 508 , 509 , 451 and 452 denied without prejudice. 469 and 493 denied as moot. Signed by Chief District Judge Thomas S Kleeh on 5/30/2023. (hrc) Modified on 5/31/2023: order was sealed mistakenly, unsealed and regenerated NEF (hrc). (Entered: 05/30/2023) (2) |
| May 30, 2023 | 514 | ORDER SETTING BRIEFING SCHEDULE. Closing Arguments to be on August 3, 2023 at 10:00 am by ZOOM. Signed by Chief District Judge Thomas S Kleeh on 5/30/2023. (hrc) (Entered: 05/30/2023) (2) |
| May 30, 2023 | 515 | ORDER denying as moot [ECF NO. 510 ] Motion. Signed by Chief District Judge Thomas S Kleeh on 5/30/2023. (jb) Modified on 5/30/2023 to edit docket text (jb). (Entered: 05/30/2023) (1) |
| May 26, 2023 | 490 | ORDER. Granting 470 , 471 , 472 , 473 , 474 , 476 , 477 , 478 , 479 , 480 , and 482 Motions For Leave To File Under Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/26/2023. (emailed to counsel of record) (hrc) Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (1) |
| May 26, 2023 | 502 | ORDER Granting 487 , 488 and 489 Motions For Leave To File Under Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/26/2023. (emailed to counsel of record) (hrc) Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (1) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) () (2) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Memo in Support) (21) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 1) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 2) (28) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Second Amended Answer) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 1) (11) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 2) (6) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 3) (5) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 4) (5) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 5) (2) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 6) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 7) (13) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 8) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 9) (10) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 10) (5) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 11) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 12) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 13) (11) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 14) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 15) (3) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 16) (3) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 17) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 18) (3) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 19) (18) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 20) (14) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 21) (16) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 22) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 23) (3) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 24) (6) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 25) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 26) (11) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 27) (28) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 28) (21) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 29) (3) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 30) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 31) (10) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 32) (13) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 33) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 34) (5) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 35) (7) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 36) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 38) (19) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 39) (27) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 40) (3) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 41) (30) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 42) (4) |
| May 26, 2023 | 505 | MOTION re [ECF No. 489 ]. (Attachments: # 1 Memo in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Second Amended Answer, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Exhibit 8, # 13 Exhibit 9, # 14 Exhibit 10, # 15 Exhibit 11, # 16 Exhibit 12, # 17 Exhibit 13, # 18 Exhibit 14, # 19 Exhibit 15, # 20 Exhibit 16, # 21 Exhibit 17, # 22 Exhibit 18, # 23 Exhibit 19, # 24 Exhibit 20, # 25 Exhibit 21, # 26 Exhibit 22, # 27 Exhibit 23, # 28 Exhibit 24, # 29 Exhibit 25, # 30 Exhibit 26, # 31 Exhibit 27, # 32 Exhibit 28, # 33 Exhibit 29, # 34 Exhibit 30, # 35 Exhibit 31, # 36 Exhibit 32, # 37 Exhibit 33, # 38 Exhibit 34, # 39 Exhibit 35, # 40 Exhibit 36, # 41 Exhibit 38, # 42 Exhibit 39, # 43 Exhibit 40, # 44 Exhibit 41, # 45 Exhibit 42, # 46 Exhibit 37) (emailed to counsel of record) (hrc) Modified to make pending motion on 5/30/2023 (hrc). Modified on 10/6/2023 to unseal per directive in 640 Order. (dk) (Entered: 05/26/2023) (Exhibit 37) (30) |
| May 23, 2023 | 485 | MOTION to Intervene FOR THE LIMITED PURPOSE OF ASSERTING THE PUBLIC INTEREST IN ACCESS TO JUDICIAL RECORDS by AMGEN USA, INC.. (Tinney, John) (Entered: 05/23/2023) (3) |
| May 23, 2023 | 486 | MEMORANDUM OF LAW IN SUPPORT by AMGEN USA, INC. re 485 MOTION to Intervene FOR THE LIMITED PURPOSE OF ASSERTING THE PUBLIC INTEREST IN ACCESS TO JUDICIAL RECORDS . (Attachments: # 1 Exhibit A)(Tinney, John) (Entered: 05/23/2023) () (15) |
| May 23, 2023 | 486 | MEMORANDUM OF LAW IN SUPPORT by AMGEN USA, INC. re 485 MOTION to Intervene FOR THE LIMITED PURPOSE OF ASSERTING THE PUBLIC INTEREST IN ACCESS TO JUDICIAL RECORDS . (Attachments: # 1 Exhibit A)(Tinney, John) (Entered: 05/23/2023) (Exhibit A) (30) |
| May 19, 2023 | 484 | Amended MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or In the Alternative for Leave to File a Surreply by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Regeneron's Surreply to Address New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment, # 2 Exhibit A)(Ruby, Steven) (Entered: 05/19/2023) () (7) |
| May 19, 2023 | 484 | Amended MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or In the Alternative for Leave to File a Surreply by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Regeneron's Surreply to Address New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment, # 2 Exhibit A)(Ruby, Steven) (Entered: 05/19/2023) (Attachment Regeneron's Surreply to Address New Arguments Raised in Mylan) (9) |
| May 19, 2023 | 484 | Amended MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or In the Alternative for Leave to File a Surreply by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Regeneron's Surreply to Address New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment, # 2 Exhibit A)(Ruby, Steven) (Entered: 05/19/2023) (Exhibit A) (2) |
| May 18, 2023 | 475 | RESPONSE in Opposition re 439 MOTION Pursuant to Rule 56(d) to Defer and Conduct Further Discovery to Adequately Oppose Summary Judgment re 428 MOTION for Summary Judgment filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 05/18/2023) (13) |
| May 18, 2023 | 481 | Proposed Order Regarding Mylan's Motion in Limine No. 1 by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 05/18/2023) (2) |
| May 18, 2023 | 483 | MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or in the Alternative for Leave to File a Surreply by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Surreply)(Ruby, Steven) (Entered: 05/18/2023) () (6) |
| May 18, 2023 | 483 | MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or in the Alternative for Leave to File a Surreply by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Surreply)(Ruby, Steven) (Entered: 05/18/2023) (Attachment Surreply) (9) |
| May 17, 2023 | 468 | ORDER; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/17/2023. (emailed to counsel of record) (hrc) (Entered: 05/17/2023) (0) |
| May 15, 2023 | 458 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Production of documents MYL-AFL0098838 through MYL-AFL0099910 (MYL-AFL 019)). (O'Brien, William) (Entered: 05/15/2023) (2) |
| May 15, 2023 | 459 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Production of documents MYL-AFL0099911 through MYL-AFL0099995 (MYL-AFL 020)). (O'Brien, William) (Entered: 05/15/2023) (2) |
| May 15, 2023 | 460 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Production of documents MYL-AFL0099996 through MYL-AFL0102176 (MYL-AFL 021-23)). (O'Brien, William) (Entered: 05/15/2023) (2) |
| May 15, 2023 | 461 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice Pursuant to 35 U.S.C. § 282). (O'Brien, William) (Entered: 05/15/2023) (2) |
| May 15, 2023 | 462 | ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/15/2023. (emailed to counsel of record) (hrc) (Entered: 05/15/2023) (0) |
| May 15, 2023 | 464 | ORDER granting 454 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/15/2023. (Emailed to Counsel) (dk) (Entered: 05/15/2023) (0) |
| May 15, 2023 | 465 | ORDER; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/15/2023. (emailed to counsel of record) (hrc) (Entered: 05/15/2023) (0) |
| May 12, 2023 | 456 | ORDER. Denied as Moot [ECF No. 299 ]. Signed by Chief District Judge Thomas S Kleeh on 5/12/2023. (hrc) (Entered: 05/12/2023) (1) |
| May 12, 2023 | 457 | ANSWER TO DEFENDANT MYLAN PHARMACEUTICALS INC.'S FIRST AMENDED COUNTERCLAIMS Other Document re 435 Answer to Counterclaim filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 05/12/2023) (27) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) () (5) |
| May 11, 2023 | 450 | MOTION in Limine (No. 2) To Exclude Testimony Relating to Claimed Subject Matter That Has Been Stipulated As Invalid by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 05/11/2023) (7) |
| May 11, 2023 | 451 | MOTION in Limine (No. 7) To Exclude and Preclude Testimony of Dr. Karl Csaky by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(O'Brien, William) (Entered: 05/11/2023) () (6) |
| May 11, 2023 | 452 | MOTION in Limine (No. 8) To Preclude The Use of Testimony From Mylan Expert Dr. Alan Ryder Relating to Claimed Subject Matter He Did Not Opine On by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(O'Brien, William) (Entered: 05/11/2023) () (7) |
| May 11, 2023 | 453 | MOTION in Limine to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Law in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Pogue, David) (Entered: 05/11/2023) () (4) |
| May 11, 2023 | 451 | MOTION in Limine (No. 7) To Exclude and Preclude Testimony of Dr. Karl Csaky by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(O'Brien, William) (Entered: 05/11/2023) (Exhibit A) (30) |
| May 11, 2023 | 452 | MOTION in Limine (No. 8) To Preclude The Use of Testimony From Mylan Expert Dr. Alan Ryder Relating to Claimed Subject Matter He Did Not Opine On by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(O'Brien, William) (Entered: 05/11/2023) (Exhibit A) (5) |
| May 11, 2023 | 452 | MOTION in Limine (No. 8) To Preclude The Use of Testimony From Mylan Expert Dr. Alan Ryder Relating to Claimed Subject Matter He Did Not Opine On by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(O'Brien, William) (Entered: 05/11/2023) (Exhibit B) (10) |
| May 11, 2023 | 452 | MOTION in Limine (No. 8) To Preclude The Use of Testimony From Mylan Expert Dr. Alan Ryder Relating to Claimed Subject Matter He Did Not Opine On by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(O'Brien, William) (Entered: 05/11/2023) (Exhibit C) (9) |
| May 11, 2023 | 453 | MOTION in Limine to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Law in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Pogue, David) (Entered: 05/11/2023) (Attachment Memorandum of Law in Support) (18) |
| May 11, 2023 | 453 | MOTION in Limine to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Law in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Pogue, David) (Entered: 05/11/2023) (Exhibit 1) (18) |
| May 11, 2023 | 453 | MOTION in Limine to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Law in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Pogue, David) (Entered: 05/11/2023) (Exhibit 2) (13) |
| May 11, 2023 | 453 | MOTION in Limine to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Law in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Pogue, David) (Entered: 05/11/2023) (Exhibit 3) (6) |
| May 11, 2023 | 453 | MOTION in Limine to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Law in Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4)(Pogue, David) (Entered: 05/11/2023) (Exhibit 4) (4) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Attachment Memorandum in Support) (7) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Attachment Regeneron's Reply In Support of Motion for Summary Judgment) (22) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Attachment Response to Mylan's Statement of Contested Facts) (19) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 14) (3) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 16) (3) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 17) (3) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 18) (7) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 19) (15) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 20) (4) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 21) (4) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 24) (2) |
| May 11, 2023 | 448 | MOTION to Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Regeneron's Reply In Support of Motion for Summary Judgment, # 3 Attachment Response to Mylan's Statement of Contested Facts, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17, # 8 Exhibit 18, # 9 Exhibit 19, # 10 Exhibit 20, # 11 Exhibit 21, # 12 Exhibit 22, # 13 Exhibit 23, # 14 Exhibit 24, # 15 Exhibit 25)(Pogue, David) Modified on 10/6/2023 to unseal per directive in Order 640 . (dk). (Entered: 05/11/2023) (Exhibit 25) (3) |
| May 10, 2023 | 447 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Supplemental Deposition of Ivan Hofmann. (Pogue, David) (Entered: 05/10/2023) (2) |
| May 9, 2023 | 446 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals, Inc.s Notice of Supplemental Deposition of Richard Manning. (Copland, Gordon) (Entered: 05/09/2023) (1) |
| May 8, 2023 | 442 | ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/8/2023. (emailed to counsel of record) (hrc) (Entered: 05/08/2023) (0) |
| May 8, 2023 | 444 | ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/8/2023. (emailed to counsel of record) (hrc) (Entered: 05/08/2023) (0) |
| May 4, 2023 | 439 | MOTION Pursuant to Rule 56(d) to Defer and Conduct Further Discovery to Adequately Oppose Summary Judgment re 428 MOTION for Summary Judgment by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1)(O'Brien, William) (Entered: 05/04/2023) () (8) |
| May 4, 2023 | 439 | MOTION Pursuant to Rule 56(d) to Defer and Conduct Further Discovery to Adequately Oppose Summary Judgment re 428 MOTION for Summary Judgment by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1)(O'Brien, William) (Entered: 05/04/2023) (Exhibit 1) (16) |
| May 2, 2023 | 437 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Supplemental Report of Richard Manning, Ph.D. (Pogue, David) (Entered: 05/02/2023) (2) |
| May 2, 2023 | 438 | Other Document Request for Denial of Motion for Presumption Under 35 U.S.C. 295, as Moot filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 05/02/2023) (4) |
| Apr 28, 2023 | 434 | ORDER GRANTING DEFENDANT'S MOTION FOR LEAVE TO FILE FIRST AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS [ECF NO. 163 ]. Signed by Chief District Judge Thomas S Kleeh on 4/28/2023. (hrc) (Entered: 04/28/2023) (1) |
| Apr 28, 2023 | 435 | DEFENDANT'S FIRST AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFF'S COMPLAINT 1 . (hrc) (Entered: 04/28/2023) (30) |
| Apr 28, 2023 | 436 | ORDER granting 364 Motion for Leave to File SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 4/28/2023. (jb) (Entered: 04/28/2023) (1) |
| Apr 27, 2023 | 433 | STIPULATION Regarding Summary Judgment and Case Narrowing by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 04/27/2023) (4) |
| Apr 25, 2023 | 431 | ORDER ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 4/25/2023. (emailed to counsel of record) (hrc) (Entered: 04/25/2023) (0) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) () (4) |
| Apr 20, 2023 | 429 | MOTION for Summary Judgment Defendant Mylan Pharmaceuticals Inc.s Motion for Summary Judgment or Partial Summary Judgment on U.S. Patent Nos. 11,104,715 (Process Patent); 11,084,865 (Formulation Patent); And 10,888,601 & 11,253,572 (Dosing Patents) by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 04/20/2023) (4) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Attachment Memorandum of Points and Authorities in Support of Regeneron's M) (12) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 1) (24) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 2) (3) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 3) (6) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 4) (12) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 5) (15) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 6) (26) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 7) (5) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 8) (7) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 9) (5) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 10) (2) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 11) (6) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 12) (8) |
| Apr 20, 2023 | 428 | MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023) (Exhibit 13) (4) |
| Apr 19, 2023 | 427 | ORDER ON CLAIM CONSTRUCTION. Signed by Chief District Judge Thomas S Kleeh on 4/19/2022. (hrc) (Entered: 04/19/2023) (30) |
| Apr 14, 2023 | 425 | ORDER DENYING EMERGENCY MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE [ECF NO. 415 ]. Signed by Chief District Judge Thomas S Kleeh on 4/14/2023. (hrc) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 426 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Amended Notice of Deposition of Bernhardt L. Trout). (O'Brien, William) (Entered: 04/14/2023) (2) |
| Apr 13, 2023 | 423 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Thomas A. Albini. (Pogue, David) (Entered: 04/13/2023) (2) |
| Apr 13, 2023 | 424 | NOTICE by Regeneron Pharmaceuticals, Inc. Regarding Plaintiff's Production Status (Pogue, David) (Entered: 04/13/2023) (4) |
| Apr 12, 2023 | 420 | RESPONSE to Motion re 415 Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1)(Ruby, Steven) (Entered: 04/12/2023) () (10) |
| Apr 12, 2023 | 421 | ORDER. The Court DIRECTED Plaintiff to produce any and all documents that it is currently able to produce by the end of the day Wednesday, April 12, 2023. The Court further DIRECTED that the balance of the documents to be produced must be produced by no later than noon on Thursday, April 13, 2023. Signed by Magistrate Judge James P. Mazzone on 4/12/2023. (hrc) (Entered: 04/12/2023) (1) |
| Apr 12, 2023 | 422 | STIPULATION Regarding Expert Discovery Following Court's April 6, 2023 Discovery Ruling by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/12/2023) (3) |
| Apr 12, 2023 | 420 | RESPONSE to Motion re 415 Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1)(Ruby, Steven) (Entered: 04/12/2023) (Exhibit 1) (5) |
| Apr 11, 2023 | 417 | MOTION for Status Conference (Unopposed) by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/11/2023) (3) |
| Apr 11, 2023 | 418 | ORDER GRANTING UNOPPOSED MOTION 417 FOR STATUS CONFERENCE. Signed by Magistrate Judge James P. Mazzone on 4/11/2023. (hrc) (Entered: 04/11/2023) (1) |
| Apr 11, 2023 | 419 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Magistrate Judge James P. Mazzone: Status Conference held on 4/11/2023. (Tape #WHG Mazzone 1 22 cv 61 Regeneron v Mylan 4 11 23) (ag) (Entered: 04/11/2023) (0) |
| Apr 10, 2023 | 413 | Memorandum in Opposition re 412 MOTION To Modify Production Deadline filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 04/10/2023) () (7) |
| Apr 10, 2023 | 414 | REPLY to Response to Motion re 412 MOTION To Modify Production Deadline filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/10/2023) (6) |
| Apr 10, 2023 | 415 | Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(O'Brien, William) (Entered: 04/10/2023) () (12) |
| Apr 10, 2023 | 416 | ORDER granting in part and denying in part 412 Motion To Modify Production Deadline filed by Regeneron Pharmaceuticals, Inc. Signed by Magistrate Judge James P. Mazzone on 4/10/2023. (hrc) (Entered: 04/10/2023) (4) |
| Apr 10, 2023 | 415 | Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(O'Brien, William) (Entered: 04/10/2023) (Exhibit A) (2) |
| Apr 10, 2023 | 415 | Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(O'Brien, William) (Entered: 04/10/2023) (Exhibit B) (3) |
| Apr 10, 2023 | 415 | Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(O'Brien, William) (Entered: 04/10/2023) (Exhibit C) (5) |
| Apr 10, 2023 | 415 | Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(O'Brien, William) (Entered: 04/10/2023) (Exhibit D) (6) |
| Apr 10, 2023 | 415 | Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(O'Brien, William) (Entered: 04/10/2023) (Exhibit E) (6) |
| Apr 10, 2023 | 413 | Memorandum in Opposition re 412 MOTION To Modify Production Deadline filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 04/10/2023) (Proposed Order) (4) |
| Apr 7, 2023 | 412 | MOTION To Modify Production Deadline by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Pogue, David) (Entered: 04/07/2023) () (5) |
| Apr 7, 2023 | 412 | MOTION To Modify Production Deadline by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Pogue, David) (Entered: 04/07/2023) (Exhibit A) (13) |
| Apr 7, 2023 | 412 | MOTION To Modify Production Deadline by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Pogue, David) (Entered: 04/07/2023) (Proposed Order) (4) |
| Apr 6, 2023 | 405 | ORDER ***SEALED***; ***SEALED*** SEALED ORDER GRANTING DEFENDANT'S 360 MOTION. Signed by Magistrate Judge James P. Mazzone on 4/6/2023. (Emailed order to counsel of record.) (snc) (Entered: 04/06/2023) (0) |
| Apr 6, 2023 | 406 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Stephen R. Russell. (Pogue, David) (Entered: 04/06/2023) (2) |
| Apr 6, 2023 | 407 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Jay M. Stewart. (Pogue, David) (Entered: 04/06/2023) (2) |
| Apr 6, 2023 | 408 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Margaret M. Snowden. (Pogue, David) (Entered: 04/06/2023) (2) |
| Apr 6, 2023 | 409 | ORDER granting 403 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 4/6/2023. (Emailed copy of order to counsel of record.) (snc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 04/06/2023) (1) |
| Apr 6, 2023 | 411 | ORDER denying 315 356 Motions; ***SEALED***; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 4/6/2023. (Emailed copy of order to counsel.) (snc) Modified on 4/6/2023 (snc). (Entered: 04/06/2023) (0) |
| Apr 5, 2023 | 404 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 4.4.23). (O'Brien, William) (Entered: 04/05/2023) (2) |
| Apr 4, 2023 | 393 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Dr. Jay M. Stewart). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 394 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Dr. Thomas A. Albini). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 395 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Francesc Godia, Ph.D.). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 396 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Ivan T. Hofmann). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 397 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Margaret M. Snowden). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 398 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Gregory MacMichael Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, Of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 399 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Reply Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 and Regarding Claims 6, 7, 12, 13, 18, 19, 22, And 23 of U.S. Patent No. 11,253,572). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 400 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Supplemental Responsive Expert Report of Gregory MacMichael, Ph.D. Regarding the Non-Infringement of Claim 18 of U.S. Patent No. 11,084,865). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 401 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 3.31.23). (O'Brien, William) (Entered: 04/04/2023) (2) |
| Apr 4, 2023 | 402 | Other Document Defendant's Submission of Supplemental Exhibits filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. 13, # 2 Exhibit Ex. 14, # 3 Exhibit Ex. 15, # 4 Exhibit Ex. 16)(Copland, Gordon) (Entered: 04/04/2023) () (3) |
| Apr 4, 2023 | 402 | Other Document Defendant's Submission of Supplemental Exhibits filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. 13, # 2 Exhibit Ex. 14, # 3 Exhibit Ex. 15, # 4 Exhibit Ex. 16)(Copland, Gordon) (Entered: 04/04/2023) (Exhibit Ex. 13) (4) |
| Apr 4, 2023 | 402 | Other Document Defendant's Submission of Supplemental Exhibits filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. 13, # 2 Exhibit Ex. 14, # 3 Exhibit Ex. 15, # 4 Exhibit Ex. 16)(Copland, Gordon) (Entered: 04/04/2023) (Exhibit Ex. 14) (3) |
| Apr 4, 2023 | 402 | Other Document Defendant's Submission of Supplemental Exhibits filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. 13, # 2 Exhibit Ex. 14, # 3 Exhibit Ex. 15, # 4 Exhibit Ex. 16)(Copland, Gordon) (Entered: 04/04/2023) (Exhibit Ex. 15) (3) |
| Apr 4, 2023 | 402 | Other Document Defendant's Submission of Supplemental Exhibits filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. 13, # 2 Exhibit Ex. 14, # 3 Exhibit Ex. 15, # 4 Exhibit Ex. 16)(Copland, Gordon) (Entered: 04/04/2023) (Exhibit Ex. 16) (11) |
| Apr 3, 2023 | 390 | SEALED ORDER GRANTING 389 MOTION; ***SEALED*** Signed by Magistrate Judge James P. Mazzone on 4/3/2023. (Copy of Order emailed to counsel.) (snc) (Entered: 04/03/2023) (0) |
| Mar 31, 2023 | 384 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Reply Expert Report of Dr. Franklin Swartzwelder Regarding Mylan's Infringement of U.S. Patent No. 11,104,715. (Pogue, David) (Entered: 03/31/2023) (2) |
| Mar 31, 2023 | 385 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Reply Expert Report of Dr. Karl Csaky. (Pogue, David) (Entered: 03/31/2023) (2) |
| Mar 31, 2023 | 386 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Reply Expert Report of Bernhardt L. Trout, Ph.D. (Pogue, David) (Entered: 03/31/2023) (2) |
| Mar 31, 2023 | 387 | ORDER GRANTING DEFENDANT'S MOTION 383 FOR HEARING TO BE CONDUCTED VIRTUALLY. Signed by Magistrate Judge James P. Mazzone on 3/31/2023. (jb) (Entered: 03/31/2023) (1) |
| Mar 31, 2023 | 388 | NOTICE of Appearance by Ben Bryant on behalf of Regeneron Pharmaceuticals, Inc. (Bryant, Ben) (Entered: 03/31/2023) (2) |
| Mar 30, 2023 | 376 | ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/30/2023. (Emailed to counsel of record) (hrc) (Entered: 03/30/2023) (0) |
| Mar 30, 2023 | 378 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Vincent Capuano). (O'Brien, William) (Entered: 03/30/2023) (2) |
| Mar 30, 2023 | 379 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Karl Csaky). (O'Brien, William) (Entered: 03/30/2023) (2) |
| Mar 30, 2023 | 380 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Richard Manning). (O'Brien, William) (Entered: 03/30/2023) (2) |
| Mar 30, 2023 | 381 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Franklin Swartzwelder). (O'Brien, William) (Entered: 03/30/2023) (2) |
| Mar 30, 2023 | 382 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Bernhardt Trout). (O'Brien, William) (Entered: 03/30/2023) (2) |
| Mar 30, 2023 | 383 | MOTION FOR HEARING TO BE CONDUCTED VIRTUALLY by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 03/30/2023) (3) |
| Mar 29, 2023 | 369 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 3.28.23). (O'Brien, William) (Entered: 03/29/2023) (2) |
| Mar 29, 2023 | 370 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Barrett E. Rabinow. (Pogue, David) (Entered: 03/29/2023) (2) |
| Mar 29, 2023 | 371 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Ivan Hofmann. (Pogue, David) (Entered: 03/29/2023) (2) |
| Mar 29, 2023 | 372 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Gregory MacMichael. (Pogue, David) (Entered: 03/29/2023) (2) |
| Mar 29, 2023 | 373 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Francesc Godia. (Pogue, David) (Entered: 03/29/2023) (2) |
| Mar 29, 2023 | 374 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Amended Notice of Deposition of Alan Ryder. (Pogue, David) (Entered: 03/29/2023) (2) |
| Mar 28, 2023 | 368 | ORDER ***SEALED***. Signed by Magistrate Judge James P. Mazzone on 3/28/2023. (Emailed to counsel of record) (hrc) (Entered: 03/28/2023) (0) |
| Mar 27, 2023 | 365 | MOTION To Take Expert Deposition on April 27, 2023 (Unopposed) by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 03/27/2023) () (3) |
| Mar 27, 2023 | 366 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 3.17.23). (O'Brien, William) (Entered: 03/27/2023) (2) |
| Mar 27, 2023 | 367 | ORDER ALLOWING EXPERT DEPOSITION TO OCCUR ON APRIL 27, 2023. Re: 365 Motion. Signed by Chief District Judge Thomas S Kleeh on 3/27/2023. (hrc) (Entered: 03/27/2023) (1) |
| Mar 27, 2023 | 365 | MOTION To Take Expert Deposition on April 27, 2023 (Unopposed) by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 03/27/2023) (Proposed Order) (1) |
| Mar 24, 2023 | 364 | MOTION for Leave to File SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Mylan Proposed Supp. Submission on Factual Developments, # 2 Exhibit Ex. 1 - Decl in Support of Supplemental Submission, # 3 Proposed Order Proposed order Granting Leave to file)(Copland, Gordon) (Entered: 03/24/2023) () (3) |
| Mar 24, 2023 | 364 | MOTION for Leave to File SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Mylan Proposed Supp. Submission on Factual Developments, # 2 Exhibit Ex. 1 - Decl in Support of Supplemental Submission, # 3 Proposed Order Proposed order Granting Leave to file)(Copland, Gordon) (Entered: 03/24/2023) (Attachment Mylan Proposed Supp. Submission on Factual Developments) (3) |
| Mar 24, 2023 | 364 | MOTION for Leave to File SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Mylan Proposed Supp. Submission on Factual Developments, # 2 Exhibit Ex. 1 - Decl in Support of Supplemental Submission, # 3 Proposed Order Proposed order Granting Leave to file)(Copland, Gordon) (Entered: 03/24/2023) (Exhibit Ex. 1 - Decl in Support of Supplemental Submission) (3) |
| Mar 24, 2023 | 364 | MOTION for Leave to File SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Mylan Proposed Supp. Submission on Factual Developments, # 2 Exhibit Ex. 1 - Decl in Support of Supplemental Submission, # 3 Proposed Order Proposed order Granting Leave to file)(Copland, Gordon) (Entered: 03/24/2023) (Proposed Order Proposed order Granting Leave to file) (1) |
| Mar 21, 2023 | 363 | ORDER The Court GRANTS the motion to withdraw [ECFNo. 362 ]. The motion to exclude and motion for emergency statusconference is WITHDRAWN [ECF No. 352 ]. Signed by Chief District Judge Thomas S Kleeh on 3/21/2023. (Regenerated NEF after unsealing order) (hrc) (Entered: 03/21/2023) (1) |
| Mar 20, 2023 | 362 | NOTICE/MOTION by Regeneron Pharmaceuticals, Inc. of Withdrawal of Motion to Exclude and Motion for Emergency Status Conference, as Moot (Attachments: # 1 Exhibit 1)(Ruby, Steven) Modified on 3/21/2023 to change event to a motion (kac). (Entered: 03/20/2023) () (4) |
| Mar 20, 2023 | 362 | NOTICE/MOTION by Regeneron Pharmaceuticals, Inc. of Withdrawal of Motion to Exclude and Motion for Emergency Status Conference, as Moot (Attachments: # 1 Exhibit 1)(Ruby, Steven) Modified on 3/21/2023 to change event to a motion (kac). (Entered: 03/20/2023) (Exhibit 1) (4) |
| Mar 17, 2023 | 359 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 357 ]; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/17/2023. (hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 03/17/2023) (1) |
| Mar 17, 2023 | 361 | ORDER ***SEALED***. Copy to counsel of record. Signed by Chief District Judge Thomas S Kleeh on 3/17/2023. (hrc) (Entered: 03/17/2023) (0) |
| Mar 16, 2023 | 354 | ORDER SCHEDULING STATUS CONFERENCE. Status Conference set for 3/23/2023 10:30 AM by Zoom before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 3/16/2023. (jb) (Entered: 03/16/2023) (2) |
| Mar 16, 2023 | 355 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 353 ]. ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/16/2023. (hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 03/16/2023) (1) |
| Mar 16, 2023 | 358 | RESPONSE by Mylan Pharmaceuticals Inc. to 350 Notice (Other). (O'Brien, William) (Entered: 03/16/2023) (5) |
| Mar 14, 2023 | 351 | ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/14/2023. (Copy to counsel of record) (jb) (Entered: 03/14/2023) (0) |
| Mar 13, 2023 | 343 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Thomas A. Albini. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 344 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Francesc Godia. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 345 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Gregory MacMichael. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 346 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Barrett E. Rabinow. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 347 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Stephen R. Russell. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 348 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Alan Ryder. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 349 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Jay M. Stewart. (Ruby, Steven) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 350 | NOTICE by Regeneron Pharmaceuticals, Inc. of Supplemental Authority Regarding Claim Construction (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 03/13/2023) () (5) |
| Mar 13, 2023 | 350 | NOTICE by Regeneron Pharmaceuticals, Inc. of Supplemental Authority Regarding Claim Construction (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 03/13/2023) (Exhibit A) (30) |
| Mar 8, 2023 | 340 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Responsive Expert Report of Dr. Franklin Swartzwelder Regarding the Validity of U.S. Patent No. 11,104,715. (Pogue, David) (Entered: 03/08/2023) (2) |
| Mar 8, 2023 | 341 | REPLY to Response to Motion re 315 MOTION to Strike DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. A - complete emal chain, # 2 Proposed Order Revised Proposed Order)(Copland, Gordon) (Entered: 03/08/2023) () (19) |
| Mar 8, 2023 | 341 | REPLY to Response to Motion re 315 MOTION to Strike DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. A - complete emal chain, # 2 Proposed Order Revised Proposed Order)(Copland, Gordon) (Entered: 03/08/2023) (Exhibit Ex. A - complete emal chain) (8) |
| Mar 8, 2023 | 341 | REPLY to Response to Motion re 315 MOTION to Strike DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Ex. A - complete emal chain, # 2 Proposed Order Revised Proposed Order)(Copland, Gordon) (Entered: 03/08/2023) (Proposed Order Revised Proposed Order) (2) |
| Mar 7, 2023 | 334 | ***SEALED***; ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 314 ]. ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (hrc) (Entered: 03/07/2023) (0) |
| Mar 7, 2023 | 336 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 322 ] ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 03/07/2023) (1) |
| Mar 7, 2023 | 338 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 324 ]; ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 03/07/2023) (1) |
| Mar 6, 2023 | 330 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 3.2.23). (O'Brien, William) (Entered: 03/06/2023) (2) |
| Mar 6, 2023 | 331 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responsive Expert Report of Alan Ryder, Ph.D.). (O'Brien, William) (Entered: 03/06/2023) (2) |
| Mar 6, 2023 | 332 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Rebuttal Expert Report of Stephen R. Russell, M.D.). (O'Brien, William) (Entered: 03/06/2023) (2) |
| Mar 6, 2023 | 333 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responsive Expert Report of Gregory MacMichael, Ph.D. Regarding the Non-Infringement of the Asserted Claims of U.S. Patent No. 11,084,865). (O'Brien, William) (Entered: 03/06/2023) (2) |
| Mar 3, 2023 | 326 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Responsive Expert Report of Bernhardt L. Trout, Ph.D. (Pogue, David) (Entered: 03/03/2023) (2) |
| Mar 3, 2023 | 327 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Responsive Expert Report of Dr. Karl Csaky. (Pogue, David) (Entered: 03/03/2023) (2) |
| Mar 3, 2023 | 328 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Report of Richard Manning, Ph.D. (Pogue, David) (Entered: 03/03/2023) (2) |
| Mar 3, 2023 | 329 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Rebuttal Expert Report of Vincent Capuano, Ph.D. (Pogue, David) (Entered: 03/03/2023) (2) |
| Mar 2, 2023 | 325 | ORDER GRANTING MOTION TO SUBSTITUTE EXHIBIT 32 [ECF NO. 300 ]. Signed by Chief District Judge Thomas S Kleeh on 3/2/2023. (hrc) (Entered: 03/02/2023) (1) |
| Mar 1, 2023 | 323 | STIPULATION EXTENDING TIME by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 03/01/2023) (3) |
| Feb 22, 2023 | 321 | ORDER Granting 318 Motion for Leave to Appear Pro Hac Vice of Rebecca A. Carter filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 2/22/2023. (hrc) (Entered: 02/22/2023) (1) |
| Feb 21, 2023 | 319 | PHV Filing Fee for Rebecca Carter paid in the amount of $200.00. Receipt number WVNC003608. (hrc) (Entered: 02/21/2023) (0) |
| Feb 21, 2023 | 320 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 2.17.23 bearing Bates number MYL-AFL0095436 through MYL-AFL0095448)). (O'Brien, William) (Entered: 02/21/2023) (2) |
| Feb 20, 2023 | 318 | MOTION for Leave to Appear Pro Hac Vice of Rebecca A. Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment A, # 2 WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 02/20/2023) () (2) |
| Feb 20, 2023 | 318 | MOTION for Leave to Appear Pro Hac Vice of Rebecca A. Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment A, # 2 WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 02/20/2023) (Attachment A) (7) |
| Feb 20, 2023 | 318 | MOTION for Leave to Appear Pro Hac Vice of Rebecca A. Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment A, # 2 WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 02/20/2023) (WVSB Receipt) (2) |
| Feb 20, 2023 | 318 | MOTION for Leave to Appear Pro Hac Vice of Rebecca A. Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment A, # 2 WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 02/20/2023) (Proposed Order) (1) |
| Feb 17, 2023 | 308 | ORDER granting 301 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (emailed counsel of record)(hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 02/17/2023) (1) |
| Feb 17, 2023 | 310 | ORDER granting 305 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (emailed to counsel)(hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 02/17/2023) (1) |
| Feb 17, 2023 | 312 | ORDER granting 307 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (emailed to counsel) (hrc) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 02/17/2023) (1) |
| Feb 17, 2023 | 315 | MOTION to Strike DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 02/17/2023) (5) |
| Feb 17, 2023 | 316 | MEMORANDUM by Mylan Pharmaceuticals Inc. re 315 MOTION to Strike DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW . (Copland, Gordon) (Entered: 02/17/2023) (19) |
| Feb 17, 2023 | 317 | Proposed Order Mylan's Proposed Order Granting Motion to Strike re 316 MEMORANDUM, by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 02/17/2023) (2) |
| Feb 10, 2023 | 302 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 2.8.23 bearing Bates numbers MYL-AFL-BLA1081261 through MYL-AFL-BLA1081389). (O'Brien, William) (Entered: 02/10/2023) (2) |
| Feb 10, 2023 | 303 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 2.8.23 bearing Bates numbers MYL-AFL0093510 through MYL-AFL0095435). (O'Brien, William) (Entered: 02/10/2023) (2) |
| Feb 10, 2023 | 304 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Supplemental Expert Report of Francesc Godia, Ph.D.). (O'Brien, William) (Entered: 02/10/2023) (2) |
| Feb 10, 2023 | 306 | Other Document Findings of Fact and Conclusions of Law on Claim Construction Submitted By Defendant Mylan Pharmaceuticals, Inc filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment proposed order on claim construction)(Copland, Gordon) (Entered: 02/10/2023) () (30) |
| Feb 10, 2023 | 306 | Other Document Findings of Fact and Conclusions of Law on Claim Construction Submitted By Defendant Mylan Pharmaceuticals, Inc filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment proposed order on claim construction)(Copland, Gordon) (Entered: 02/10/2023) (Attachment proposed order on claim construction) (4) |
| Feb 6, 2023 | 290 | CORRECTED Other Document re 278 Certificate of Service (Opening Expert Report of Dr. Jay M. Stewart) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 291 | CORRECTED Other Document re 279 Certificate of Service (Opening Expert Report of Francesc Godia, Ph.D.) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 292 | CORRECTED Other Document re 280 Certificate of Service (Opening Expert Report of Dr. Thomas A. Albini) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 293 | CORRECTED Other Document re 281 Certificate of Service, (Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Mylans Construction of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 294 | CORRECTED Other Document re 282 Certificate of Service, (Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 295 | CORRECTED Other Document re 283 Certificate of Service, (Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Mylans Proposed Constructions of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 296 | CORRECTED Other Document re 284 Certificate of Service, (Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 297 | ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/6/2023. Copy to counsel of record.(cmd) (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | 298 | ORDER ***SEALED***; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/6/2023. (Emailed to Counsel) (dk) (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | 299 | *** SEALED *** MOTION for Presumption Under35 U.S.C. §295 by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18, # 20 Exhibit 19, # 21 Exhibit 20, # 22 Exhibit 21, # 23 Exhibit 22, # 24 Exhibit 23, # 25 Exhibit 24, # 26 Exhibit 25, # 27 Exhibit 26, # 28 Exhibit 27, # 29 Exhibit 28, # 30 Exhibit 29, # 31 Exhibit 30, # 32 Exhibit 31, # 33 Exhibit 32, # 34 Exhibit 33, # 35 Exhibit 34, # 36 Exhibit 35, # 37 Exhibit 36, # 38 Exhibit 37, # 39 Exhibit 37 part 2, # 40 Exhibit 38, # 41 Exhibit 39, # 42 Exhibit 40)(cmd) (Attachment 33 replaced on 3/2/2023 PER ORDER 325 ) (hrc). (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | 300 | MOTION to Substitute Exhibit 32 to Regeneron's Motion for Presumption under 35 U.S.C. 295 by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Amended Exhibit 32 (to be filed under seal))(Pogue, David) (Entered: 02/06/2023) () (4) |
| Feb 6, 2023 | 300 | MOTION to Substitute Exhibit 32 to Regeneron's Motion for Presumption under 35 U.S.C. 295 by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Amended Exhibit 32 (to be filed under seal))(Pogue, David) (Entered: 02/06/2023) (Attachment Amended Exhibit 32 (to be filed under seal)) (1) |
| Feb 3, 2023 | 277 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 2.3.23). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 278 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Dr. Jay M. Stewart). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 279 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Francesc Godia, Ph.D.). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 280 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Dr. Thomas A. Albini). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 281 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Mylans Construction of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 282 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 283 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Mylans Proposed Constructions of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 284 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572). (O'Brien, William) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 285 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Amended Notice of Deposition of Rebecca Rinker. (Pogue, David) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 287 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Opening Expert Report of Bernhardt L. Trout, PH.D.. (Pogue, David) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 288 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Opening Expert Report of Karl G. Csaky, M.D., Ph. D. Regarding Infringement of U.S. Patent Nos. 11,253,572 and 10,888,601. (Pogue, David) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 289 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Opening Expert Report and Declaration of Dr. Franklin Swartzwelder Regarding Mylan's Infringement of U.S. Patent No. 11,104,715. (Pogue, David) (Entered: 02/03/2023) (2) |
| Jan 27, 2023 | 273 | TRANSCRIPT PURCHASE ORDER by Mylan Pharmaceuticals Inc. for proceedings held on 1/24/2023 before Judge Kleeh. (ck) (Entered: 01/27/2023) (2) |
| Jan 27, 2023 | 274 | TRANSCRIPT PURCHASE ORDER by Regeneron Pharmaceuticals, Inc. for proceedings held on 1/24/2023 before Judge Kleeh. (ck) (Entered: 01/27/2023) (2) |
| Jan 27, 2023 | 275 | STIPULATED SUPPLEMENTAL PROTECTIVE ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/27/2023. (dk) (Entered: 01/27/2023) (6) |
| Jan 27, 2023 | 276 | REPLY to Response to Motion re 175 MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/27/2023) () (17) |
| Jan 27, 2023 | 276 | REPLY to Response to Motion re 175 MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/27/2023) (Exhibit A) (4) |
| Jan 26, 2023 | 269 | CLAIM CONSTRUCTION SLIDES ( Other Document ) filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment)(O'Brien, William) (Entered: 01/26/2023) () (2) |
| Jan 26, 2023 | 270 | TRANSCRIPT of claim construction hearing held on 1/24/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 2/16/2023. Redacted Transcript Deadline set for 2/27/2023. Release of Transcript Restriction set for 4/26/2023. (ck) (Entered: 01/26/2023) (169) |
| Jan 26, 2023 | 271 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Third Amended Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)). (O'Brien, William) (Entered: 01/26/2023) (2) |
| Jan 26, 2023 | 272 | STIPULATION and Request for Entry of Agreed Supplemental Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 01/26/2023) () (2) |
| Jan 26, 2023 | 272 | STIPULATION and Request for Entry of Agreed Supplemental Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 01/26/2023) (Proposed Order) (6) |
| Jan 26, 2023 | 269 | CLAIM CONSTRUCTION SLIDES ( Other Document ) filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment)(O'Brien, William) (Entered: 01/26/2023) (Attachment) (30) |
| Jan 24, 2023 | 266 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Markman Hearing held on 1/24/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 01/24/2023) (0) |
| Jan 24, 2023 | 267 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Second Amended Notice of Deposition of Abhijit Barve. (Pogue, David) (Entered: 01/24/2023) (2) |
| Jan 24, 2023 | 268 | CLAIM CONSTRUCTION PRESENTATION filed by Regeneron Pharmaceuticals, Inc. (dk) (Entered: 01/25/2023) (30) |
| Jan 23, 2023 | 262 | RESPONSE by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1)(Ruby, Steven) (Entered: 01/23/2023) () (4) |
| Jan 23, 2023 | 263 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 261 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 1/23/2023. (Emailed to Counsel) (dk) Modified on 10/6/2023 unsealed per 640 order (snc). (Entered: 01/23/2023) (1) |
| Jan 23, 2023 | 264 | *** SEALED *** DEFENDANT'S MOTION TO STRIKE PLAINTIFF'S UNAUTHORIZED REPLY BRIEF (ECF. NO. 228 ) ON CLAIM CONSTRUCTION ISSUES OR, ALTERNATIVELY, FOR LEAVE TO FILE RESPONSE by Mylan Pharmaceuticals Inc. (Attachments: # 1 Defendant's Alternative Submission, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H) (Filed under seal per 263 Order. (dk) (Entered: 01/23/2023) (0) |
| Jan 23, 2023 | 265 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.20.23). (O'Brien, William) (Entered: 01/23/2023) (2) |
| Jan 23, 2023 | 262 | RESPONSE by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1)(Ruby, Steven) (Entered: 01/23/2023) (Exhibit 1) (5) |
| Jan 20, 2023 | 260 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Answers and Objections to Regeneron's Fourth Set of Interrogatories (Nos. 6-14)). (O'Brien, William) (Entered: 01/20/2023) (2) |
| Jan 18, 2023 | 255 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.17.23). (O'Brien, William) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 256 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's Second Set of Interrogatories (Nos. 18-24). (Pogue, David) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 257 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Mylan Pharmaceuticals Inc.'s Third Requests for Production of Documents and Things (Nos. 156-161). (Pogue, David) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 258 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Amended Notice of Deposition of Abhijit Barve. (Pogue, David) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 259 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Rebecca Rinker. (Pogue, David) (Entered: 01/18/2023) (2) |
| Jan 17, 2023 | 247 | NOTICE of Appearance by Stephenee Raychel Gandee on behalf of Mylan Pharmaceuticals Inc. (Gandee, Stephenee) (Entered: 01/17/2023) (3) |
| Jan 17, 2023 | 248 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Hanne Bak). (O'Brien, William) (Entered: 01/17/2023) (2) |
| Jan 17, 2023 | 249 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.16.23). (O'Brien, William) (Entered: 01/17/2023) (2) |
| Jan 17, 2023 | 250 | MOTION for Extension of Time to File Response/Reply in Support of Plaintiff's Motion for Judgment on the Pleadings by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 01/17/2023) () (3) |
| Jan 17, 2023 | 251 | ORDER granting 246 Motion to Seal ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 1/17/2023. (Emailed to counsel) (dk) Modified on 10/6/2023 unsealed per order 640 (mas). (Entered: 01/17/2023) (1) |
| Jan 17, 2023 | 252 | MYLAN'S RESPONSE IN OPPOSITION TO REGENERON'S MOTION FOR JUDGMENT ON THE PLEADINGS AS TO MYLAN'S INEQUITABLE CONDUCT DEFENSES AND COUNTERCLAIMS. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22) (Filed under seal per 251 Order) (dk) (Entered: 01/17/2023) (0) |
| Jan 17, 2023 | 253 | ORDER. ORDERS that Regeneron's Reply in Support of Plaintiff's Motion for Judgment on the Pleadings shall be filed on or before January 27, 2023. Signed by Chief District Judge Thomas S Kleeh on 1/17/2023. (dk) (Entered: 01/17/2023) (1) |
| Jan 17, 2023 | 254 | NOTICE by Mylan Pharmaceuticals Inc. NOTICE OF SUPPLEMENTAL AUTHORITY REGARDING CLAIM CONSTRUCTION (Attachments: # 1 Attachment PTAB institution decision 681 Patent, # 2 Attachment PTAB institution decision 601 Patent, # 3 Attachment PTAB final decision 338 Patent)(Copland, Gordon) (Entered: 01/17/2023) () (4) |
| Jan 17, 2023 | 250 | MOTION for Extension of Time to File Response/Reply in Support of Plaintiff's Motion for Judgment on the Pleadings by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 01/17/2023) (Proposed Order) (1) |
| Jan 17, 2023 | 254 | NOTICE by Mylan Pharmaceuticals Inc. NOTICE OF SUPPLEMENTAL AUTHORITY REGARDING CLAIM CONSTRUCTION (Attachments: # 1 Attachment PTAB institution decision 681 Patent, # 2 Attachment PTAB institution decision 601 Patent, # 3 Attachment PTAB final decision 338 Patent)(Copland, Gordon) (Entered: 01/17/2023) (Attachment PTAB institution decision 681 Patent) (30) |
| Jan 17, 2023 | 254 | NOTICE by Mylan Pharmaceuticals Inc. NOTICE OF SUPPLEMENTAL AUTHORITY REGARDING CLAIM CONSTRUCTION (Attachments: # 1 Attachment PTAB institution decision 681 Patent, # 2 Attachment PTAB institution decision 601 Patent, # 3 Attachment PTAB final decision 338 Patent)(Copland, Gordon) (Entered: 01/17/2023) (Attachment PTAB institution decision 601 Patent) (30) |
| Jan 17, 2023 | 254 | NOTICE by Mylan Pharmaceuticals Inc. NOTICE OF SUPPLEMENTAL AUTHORITY REGARDING CLAIM CONSTRUCTION (Attachments: # 1 Attachment PTAB institution decision 681 Patent, # 2 Attachment PTAB institution decision 601 Patent, # 3 Attachment PTAB final decision 338 Patent)(Copland, Gordon) (Entered: 01/17/2023) (Attachment PTAB final decision 338 Patent) (30) |
| Jan 13, 2023 | 230 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Plaintiff's Second Supplemental Rule 26(a) Initial Disclosures. (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 231 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 10,888,601. (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 232 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 11,084,865. (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 233 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 11,104,715. (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 234 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 11,253,572. (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 235 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Mylan Pharmaceuticals Inc.'s Second Requests for the Production of Documents and Things (Nos. 121-155). (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 236 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Responses and Objections to Mylan Pharmaceuticals Inc.'s First Requests for Admission (Nos. 1-35). (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 237 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-17). (Pogue, David) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 238 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responses and Objections to Regeneron's Second Requests for Admission (Nos. 22-39). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 239 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.9.23). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 240 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.10.23). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 241 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.11.23). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 242 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Second Amended Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 243 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Answers and Objections to Regeneron's Third Set of Interrogatories (No. 5)). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 244 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 1.12.23). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 245 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Invalidity Contentions Regarding U.S. Patent Nos. 10,888,601, 11,084,865, 11,104,715, and 11,253,572). (O'Brien, William) (Entered: 01/13/2023) (2) |
| Jan 12, 2023 | 227 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 226 ). Signed by Chief District Judge Thomas S Kleeh on 1/12/2023. (Emailed to Counsel) (dk) (Entered: 01/12/2023) (0) |
| Jan 12, 2023 | 229 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Second Amended Notice of Deposition of Hana Chang. (Pogue, David) (Entered: 01/12/2023) (2) |
| Jan 11, 2023 | 224 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. documents bearing Bates numbers MYL-AFL-BLA1081206 through MYL-AFL-BLA1081258. (Copland, Gordon) (Entered: 01/11/2023) (2) |
| Jan 11, 2023 | 225 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. attachments to the documents bearing Bates Numbers MYL-AFL0018104, MYL-AFL0018949, MYL-AFL0045092, MYL-AFL0081201, MYL-AFL0082770, MYL-AFL0082773 and MYL-AFL0082800. (Copland, Gordon) (Entered: 01/11/2023) (2) |
| Jan 6, 2023 | 216 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Amended Notice of Deposition of Hana Chang. (Pogue, David) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 217 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Abby Cahn. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 218 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of George D. Yancopoulos. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 219 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Ken Graham. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 220 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Eric Furfine. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 221 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Eric Furfine. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 222 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Frank Cottingham. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 223 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Jennifer Colyer. (Copland, Gordon) (Entered: 01/06/2023) (2) |
| Jan 5, 2023 | 212 | ORDER granting 207 Motion for Leave to Appear Pro Hac Vice of (Jake R. Ritthamel) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 1/05/2023. (jb) (Entered: 01/05/2023) (1) |
| Jan 5, 2023 | 213 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Sai Patil. (Pogue, David) (Entered: 01/05/2023) (2) |
| Jan 5, 2023 | 214 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Parag Goyal. (Pogue, David) (Entered: 01/05/2023) (2) |
| Jan 5, 2023 | 215 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Uwe Niesner. (Pogue, David) (Entered: 01/05/2023) (2) |
| Jan 4, 2023 | 211 | Pro Hac Vice Filing Fee for J. Ritthamel in the amount of $200.00. Receipt Number WVNC003571. (jb) (Entered: 01/04/2023) (0) |
| Jan 3, 2023 | 209 | ORDER. For reasons appearing to the Court, the Markman hearing previously scheduled for January 6, 2023, is CONTINUED until January 24, 2023, 11:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 1/3/2023. (dk) (Entered: 01/03/2023) (1) |
| Jan 3, 2023 | 210 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Amended Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)). (O'Brien, William) (Entered: 01/03/2023) (2) |
| Jan 2, 2023 | 208 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Rajesh Nachankar. (Pogue, David) (Entered: 01/02/2023) (2) |
| Dec 30, 2022 | 202 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Hana Chang. (Pogue, David) (Entered: 12/30/2022) (2) |
| Dec 30, 2022 | 203 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Karl Bozicevic). (O'Brien, William) (Entered: 12/30/2022) (2) |
| Dec 30, 2022 | 204 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Subpoena to Bozicevic, Field & Francis LLP). (O'Brien, William) (Entered: 12/30/2022) (2) |
| Dec 30, 2022 | 205 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Answers and Objections to Regeneron's Second Set of Interrogatories (Nos. 3-4)). (O'Brien, William) (Entered: 12/30/2022) (2) |
| Dec 30, 2022 | 206 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responses and Objections to Plaintiff's Fourth Request for Production of Documents (Nos. 39-45)). (O'Brien, William) (Entered: 12/30/2022) (2) |
| Dec 30, 2022 | 207 | MOTION for Leave to Appear Pro Hac Vice (Jake R. Ritthamel) by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 12/30/2022) () (4) |
| Dec 30, 2022 | 207 | MOTION for Leave to Appear Pro Hac Vice (Jake R. Ritthamel) by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 12/30/2022) (Proposed Order) (1) |
| Dec 29, 2022 | 201 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Amended Notice of Deposition of Prasanna Ganapathi. (Pogue, David) (Entered: 12/29/2022) (2) |
| Dec 28, 2022 | 198 | ORDER granting 189 Mylan Pharmaceuticals Inc.'s Motion for Extension of Time to File Response to Plaintiff's 175 Motion for Judgment on the Pleadings. Mylan's response is due by 1/13/2023. Signed by Chief District Judge Thomas S Kleeh on 12/28/2022. (jb) (Entered: 12/28/2022) (1) |
| Dec 28, 2022 | 199 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Plaintiff's First Supplemental Rule 26(a) Initial Disclosures. (Pogue, David) (Entered: 12/28/2022) (2) |
| Dec 28, 2022 | 200 | NOTICE of Appearance by Raymond S Franks, II on behalf of Regeneron Pharmaceuticals, Inc. (Franks, Raymond) (Entered: 12/28/2022) (2) |
| Dec 27, 2022 | 197 | ORDER granting 192 Motion for Leave to Appear Pro Hac Vice of Grace W. Knofczynski filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/27/2022. (jb) (Entered: 12/27/2022) (1) |
| Dec 22, 2022 | 190 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Service of Subpoena. (Pogue, David) (Entered: 12/22/2022) (2) |
| Dec 22, 2022 | 191 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. Notice of Service of Subpoena. (Pogue, David) (Entered: 12/22/2022) (2) |
| Dec 22, 2022 | 192 | MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/22/2022) () (2) |
| Dec 22, 2022 | 193 | Pro Hac Vice Filing Fee for G. Knofczynski in the amount of $ 200.00 paid. Receipt Number WVNC003568. (jb) (Entered: 12/22/2022) (0) |
| Dec 22, 2022 | 194 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Alois Jungbauer. (Pogue, David) (Entered: 12/22/2022) (2) |
| Dec 22, 2022 | 195 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Gregory MacMichael. (Pogue, David) (Entered: 12/22/2022) (2) |
| Dec 22, 2022 | 196 | RESPONSE to Motion re 189 MOTION for Extension of Time to File Response/Reply as to 175 MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 12/22/2022) (3) |
| Dec 22, 2022 | 192 | MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/22/2022) (Exhibit WVSB Receipt) (2) |
| Dec 22, 2022 | 192 | MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/22/2022) (Proposed Order) (1) |
| Dec 21, 2022 | 189 | MOTION for Extension of Time to File Response/Reply as to 175 MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 12/21/2022) () (5) |
| Dec 21, 2022 | 189 | MOTION for Extension of Time to File Response/Reply as to 175 MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 12/21/2022) (Proposed Order) (1) |
| Dec 20, 2022 | 183 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Second Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 18-24)). (O'Brien, William) (Entered: 12/20/2022) (2) |
| Dec 20, 2022 | 184 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Third Requests for the Production of Documents and Things to Regeneron (Nos. 156-161)). (O'Brien, William) (Entered: 12/20/2022) (2) |
| Dec 20, 2022 | 185 | ORDER granting 173 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/20/2022. (Emailed to Counsel) (dk) Modified on 10/6/2023 unsealed per order 640 (mas). (Entered: 12/20/2022) (1) |
| Dec 20, 2022 | 186 | ORDER granting 174 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/20/2022. (Emailed to Counsel) (dk) Modified on 10/6/2023 unsealed per order 640 (mas). (Entered: 12/20/2022) (1) |
| Dec 20, 2022 | 187 | DEFENDANT MYLAN PHARMACEUTICALS INC.'S RESPONSIVE CLAIM CONSTRUCTION BRIEF filed by Mylan Pharmaceuticals Inc. (Attachments: # 1 Exhibit 65, # 2 Exhibit 66, # 3 Exhibit 67, # 4 Exhibit 68, # 5 Exhibit 69, # 6 Exhibit 70, # 7 Exhibit 71, # 8 Exhibit 72, # 9 Exhibit 73, # 10 Exhibit 74, # 11 Exhibit 75, # 12 Exhibit 76) (Filed under seal per 185 Order) (dk) (Entered: 12/20/2022) (0) |
| Dec 20, 2022 | 188 | REGENERON'S RESPONSIVE CLAIM CONSTRUCTION BRIEF filed by Regeneron Pharmaceuticals, Inc. (Attachments: # 1 Exhibit 22, # 2 Exhibit 23, # 3 Exhibit 24, # 4 Exhibit 25, # 5 Exhibit 26, # 6 Exhibit 27, # 7 Exhibit 28, # 8 Exhibit 29, # 9 Exhibit 30, # 10 Exhibit 31, # 11 Exhibit 32, # 12 Exhibit 33, # 13 Exhibit 34, # 14 Exhibit 35, # 15 Exhibit 36, # 16 Exhibit 37, # 17 Exhibit 38, # 18 Exhibit 39, # 19 Exhibit 40, # 20 Exhibit 41, # 21 Exhibit 42, # 22 Exhibit 43, # 23 Exhibit 44, # 24 Exhibit 45) (Filed under seal per 186 Order) (dk) (Entered: 12/20/2022) (0) |
| Dec 19, 2022 | 177 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (First Set of Requests for Admission to Regeneron Pharmaceuticals, Inc. (Nos. 1-35)). (O'Brien, William) (Entered: 12/19/2022) (2) |
| Dec 19, 2022 | 178 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)). (O'Brien, William) (Entered: 12/19/2022) (2) |
| Dec 19, 2022 | 179 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (First Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 1-17)). (O'Brien, William) (Entered: 12/19/2022) (2) |
| Dec 19, 2022 | 180 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Second Requests for the Production of Documents and Things to Regeneron (Nos. 121-155)). (O'Brien, William) (Entered: 12/19/2022) (2) |
| Dec 19, 2022 | 181 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responses and Objections to Plaintiff's First Requests for Admission (Nos. 1-21)). (O'Brien, William) (Entered: 12/19/2022) (2) |
| Dec 19, 2022 | 182 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Fourth Set of Interrogatories to Mylan Pharmaceuticals Inc.. (Pogue, David) (Entered: 12/19/2022) (2) |
| Dec 16, 2022 | 175 | MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Regeneron Pharmaceuticals, Inc.. Responses due by 12/30/2022 (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Ruby, Steven) (Entered: 12/16/2022) () (3) |
| Dec 16, 2022 | 176 | Memorandum in Support re 175 MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 12/16/2022) (20) |
| Dec 16, 2022 | 175 | MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Regeneron Pharmaceuticals, Inc.. Responses due by 12/30/2022 (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Ruby, Steven) (Entered: 12/16/2022) (Exhibit A) (11) |
| Dec 16, 2022 | 175 | MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Regeneron Pharmaceuticals, Inc.. Responses due by 12/30/2022 (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Ruby, Steven) (Entered: 12/16/2022) (Exhibit B) (30) |
| Dec 16, 2022 | 175 | MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Regeneron Pharmaceuticals, Inc.. Responses due by 12/30/2022 (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Ruby, Steven) (Entered: 12/16/2022) (Exhibit C) (10) |
| Dec 16, 2022 | 175 | MOTION for Judgment on the Pleadings as to Defendant's Inequitable Conduct Defenses and Counterclaims by Regeneron Pharmaceuticals, Inc.. Responses due by 12/30/2022 (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Ruby, Steven) (Entered: 12/16/2022) (Exhibit D) (11) |
| Dec 15, 2022 | 173 | MOTION to Seal Defendant Mylan Pharmaceuticals Inc.'s Responsive Claim Construction Brief by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment Mylan's Responsive Claim Construction Brief, # 2 Exhibit Ex. 65, # 3 Exhibit Ex. 66, # 4 Exhibit Ex. 67, # 5 Exhibit Ex. 68, # 6 Exhibit Ex. 69, # 7 Exhibit Ex. 70, # 8 Exhibit Ex. 71, # 9 Exhibit Ex. 72, # 10 Exhibit Ex. 73, # 11 Exhibit Ex. 74, # 12 Exhibit Ex. 75, # 13 Exhibit Ex. 76)(Copland, Gordon) Modified on 10/6/2023 unsealed per order 640 (mas). (Entered: 12/15/2022) () (6) |
| Dec 14, 2022 | 169 | NOTICE of Appearance by John D. Pizzo on behalf of Mylan Pharmaceuticals Inc. (Pizzo, John) (Entered: 12/14/2022) (3) |
| Dec 14, 2022 | 170 | NOTICE of Appearance by Garrett Matthew Spiker on behalf of Mylan Pharmaceuticals Inc. (Spiker, Garrett) (Entered: 12/14/2022) (3) |
| Dec 14, 2022 | 171 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Wayne Talton. (Pogue, David) (Entered: 12/14/2022) (2) |
| Dec 14, 2022 | 172 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Ash Patel. (Pogue, David) (Entered: 12/14/2022) (2) |
| Dec 13, 2022 | 167 | ORDER GRANTING WITHDRAWAL OF MOTION TO COMPEL. Plaintiff's request to WITHDRAW its Motion to Compel is GRANTED. Plaintiff's Motion 143 is TERMINATED. Further, the hearing currently set for December 15, 2022, is CANCELLED. Signed by Magistrate Judge James P. Mazzone on 12/13/2022. (dk) (Entered: 12/13/2022) (1) |
| Dec 13, 2022 | 168 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiff's Third Set of Requests for the Production of Documents (Nos. 28-38)). (O'Brien, William) (Entered: 12/13/2022) (2) |
| Dec 12, 2022 | 165 | Withdrawal Other Document re 143 MOTION to Compel Compliance with the Protective Order filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 12/12/2022) (3) |
| Dec 12, 2022 | 166 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Third Set of Interrogatories to Mylan Pharmaceuticals Inc.. (Ruby, Steven) (Entered: 12/12/2022) (2) |
| Dec 9, 2022 | 157 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 11.16.22). (Copland, Gordon) (Entered: 12/09/2022) (2) |
| Dec 9, 2022 | 158 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 12.7.22). (Copland, Gordon) (Entered: 12/09/2022) (2) |
| Dec 9, 2022 | 159 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Karen Chu). (Copland, Gordon) (Entered: 12/09/2022) (2) |
| Dec 9, 2022 | 160 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Amy Johnson). (Copland, Gordon) (Entered: 12/09/2022) (2) |
| Dec 9, 2022 | 161 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Shawn Lawrence). (Copland, Gordon) (Entered: 12/09/2022) (2) |
| Dec 9, 2022 | 162 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Notice of Deposition of Andrew Tustian). (Copland, Gordon) (Entered: 12/09/2022) (2) |
| Dec 9, 2022 | 163 | MOTION for Leave to File First Amended Answer, Defenses, and Counterclaims by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment First Amended Answer, Defenses, and Counterclaims)(O'Brien, William) (Entered: 12/09/2022) () (3) |
| Dec 9, 2022 | 164 | MEMORANDUM of Law in Support of Defendant's Motion for Leave to Amend Its Answer, Defenses, and Counterclaims by Mylan Pharmaceuticals Inc. re 163 MOTION for Leave to File First Amended Answer, Defenses, and Counterclaims . (O'Brien, William) (Entered: 12/09/2022) (6) |
| Dec 9, 2022 | 163 | MOTION for Leave to File First Amended Answer, Defenses, and Counterclaims by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Attachment First Amended Answer, Defenses, and Counterclaims)(O'Brien, William) (Entered: 12/09/2022) (Attachment First Amended Answer, Defenses, and Counterclaims) (30) |
| Dec 8, 2022 | 147 | ***VACATED PER 148 ORDER*** ORDER OF REFERRAL. Pursuant to 28 U.S.C. § 636, the motion 143 is REFERRED to United States Magistrate Judge Michael J. Aloi for disposition. In ruling on the motion, the Magistrate Judge is authorized to consider the record, conduct a hearing if necessary, and do all things proper to render a decision. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (Copy to MJ Aloi and Counsel) (dk) Modified on 12/8/2022 (dk). (Entered: 12/08/2022) (1) |
| Dec 8, 2022 | 148 | ORDER OF REFERRAL. For reasons appearing to the Court, its previous order of referral is VACATED (ECF No. 147 ). Pursuant to 28 U.S.C. § 636, Plaintiff's motion to compel (ECF No. 143 ) is REFERRED to United States Magistrate Judge James P. Mazzone for disposition. In ruling on the motion, the Magistrate Judge is authorized to consider the record, conduct a hearing if necessary, and do all things proper to render a decision. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (Copy MJ Mazzone, Counsel) (dk) (Entered: 12/08/2022) (1) |
| Dec 8, 2022 | 149 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 12.2.22). (O'Brien, William) (Entered: 12/08/2022) (2) |
| Dec 8, 2022 | 150 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 12.7.22). (O'Brien, William) (Entered: 12/08/2022) (2) |
| Dec 8, 2022 | 151 | ORDER granting 142 Motion of Adam J. Bernstein for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (dk) (Entered: 12/08/2022) (1) |
| Dec 8, 2022 | 152 | ORDER granting 141 Motion of Arunabha Bhoumik for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (dk) (Entered: 12/08/2022) (1) |
| Dec 8, 2022 | 153 | ORDER SETTING BRIEFING SCHEDULE AND ORAL ARGUMENT/EVIDENTIARY HEARING re 143 MOTION to Compel Compliance with the Protective Order filed by Regeneron Pharmaceuticals, Inc. Responses due by 12/13/2022. Evidentiary Hearing set for 12/15/2022 10:00 AM in Wheeling Magistrate Judge Courtroom, 4th Floor before Magistrate Judge James P. Mazzone. Signed by Magistrate Judge James P. Mazzone on 12/8/2022. (dk) (Entered: 12/08/2022) (1) |
| Dec 8, 2022 | 154 | MOTION for Leave to Appear Pro Hac Vice (Deanne D. Mazzochi) by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 12/08/2022) () (3) |
| Dec 8, 2022 | 155 | Pro Hac Vice Filing Fee for D. Mazzochi in the amount of $ 200.00. Receipt number WVNC003561. (jb) (Entered: 12/08/2022) (0) |
| Dec 8, 2022 | 156 | ORDER granting 154 Motion of Deanne D. Mazzochi for Leave to Appear Pro Hac Vice on behalf of Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (dk) (Entered: 12/08/2022) (1) |
| Dec 8, 2022 | 154 | MOTION for Leave to Appear Pro Hac Vice (Deanne D. Mazzochi) by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 12/08/2022) (Proposed Order) (1) |
| Dec 7, 2022 | 144 | Pro Hac Vice Filing Fee for A. Bhoumik and A. Bernstein in the amount of $400.00. Receipt number WVNC003558. (jb) Modified on 12/7/2022 to edit docket text (jb). (Entered: 12/07/2022) (0) |
| Dec 7, 2022 | 145 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Second Requests for Admission to Mylan Pharmaceuticals Inc. (Pogue, David) (Entered: 12/07/2022) (2) |
| Dec 6, 2022 | 141 | MOTION for Leave to Appear Pro Hac Vice of Arunabha Bhoumik by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) () (2) |
| Dec 6, 2022 | 142 | MOTION for Leave to Appear Pro Hac Vice of Adam J. Bernstein by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) () (2) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) () (3) |
| Dec 6, 2022 | 142 | MOTION for Leave to Appear Pro Hac Vice of Adam J. Bernstein by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Attachment WVSB Receipt) (2) |
| Dec 6, 2022 | 142 | MOTION for Leave to Appear Pro Hac Vice of Adam J. Bernstein by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Proposed Order) (1) |
| Dec 6, 2022 | 141 | MOTION for Leave to Appear Pro Hac Vice of Arunabha Bhoumik by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Attachment WVSB Receipt) (2) |
| Dec 6, 2022 | 141 | MOTION for Leave to Appear Pro Hac Vice of Arunabha Bhoumik by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Proposed Order) (1) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Attachment Memorandum In Support) (14) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Exhibit 1) (7) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Exhibit 2) (9) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Exhibit 3) (7) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Exhibit 4) (3) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Exhibit 5) (6) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Exhibit 6) (2) |
| Dec 6, 2022 | 143 | MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum In Support, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Proposed Order)(Ruby, Steven) (Entered: 12/06/2022) (Proposed Order) (2) |
| Dec 5, 2022 | 137 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Abhijit Barve. (Pogue, David) (Entered: 12/05/2022) (2) |
| Dec 5, 2022 | 138 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Prasanna Ganapathi. (Pogue, David) (Entered: 12/05/2022) (2) |
| Dec 5, 2022 | 139 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Keri Vaughan. (Pogue, David) (Entered: 12/05/2022) (2) |
| Dec 5, 2022 | 140 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Defendants Notice of Rule 30(b)(6) Deposition of Plaintiff Regeneron Pharmaceuticals, Inc. (Copland, Gordon) (Entered: 12/05/2022) (2) |
| Dec 1, 2022 | 132 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 106 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/1/2022. (Emailed to Counsel) (dk) (Entered: 12/01/2022) (0) |
| Dec 1, 2022 | 134 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 119 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/1/2022. (Emailed to Counsel) (dk) (Entered: 12/01/2022) (0) |
| Dec 1, 2022 | 136 | ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 122 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/1/2022. (Emailed to Counsel) (dk) (Entered: 12/01/2022) (0) |
| Nov 30, 2022 | 125 | Pro Hac Vice Filing fee for H. Bernal Anderson, S. Douglass and R. Griffin in the amount of $600.00 paid. Receipt number WVNC003546. (jb) (Entered: 11/30/2022) (0) |
| Nov 30, 2022 | 126 | ORDER granting 117 Motion of Mary Charlotte Y. Carroll for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022) (1) |
| Nov 30, 2022 | 127 | ORDER granting 116 Motion of Evan T. Leo for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022) (1) |
| Nov 30, 2022 | 128 | ORDER granting 115 Motion of Jacob E. Hartman for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022) (1) |
| Nov 30, 2022 | 129 | ORDER granting 114 Motion of Sven E. Henningson, III for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022) (1) |
| Nov 30, 2022 | 130 | ORDER granting 113 Motion of Andrew E. Goldsmith for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022) (1) |
| Nov 30, 2022 | 131 | NOTICE by Regeneron Pharmaceuticals, Inc. of Deposition of Defendant Mylan Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) (Pogue, David) (Entered: 11/30/2022) (12) |
| Nov 29, 2022 | 113 | MOTION for Leave to Appear Pro Hac Vice of Andrew E. Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Main Document) (2) |
| Nov 29, 2022 | 114 | MOTION for Leave to Appear Pro Hac Vice of Sven Eric Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Main Document) (2) |
| Nov 29, 2022 | 115 | MOTION for Leave to Appear Pro Hac Vice of Jacob E. Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Main Document) (2) |
| Nov 29, 2022 | 116 | MOTION for Leave to Appear Pro Hac Vice of Evan T. Leo by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Main Document) (2) |
| Nov 29, 2022 | 117 | MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Main Document) (2) |
| Nov 29, 2022 | 118 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment Subpoena)(Pogue, David) (Entered: 11/29/2022) (Main Document) (2) |
| Nov 29, 2022 | 120 | MEMORANDUM of Law in Support of Motion for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc. . (Pogue, David) (Entered: 11/29/2022) (4) |
| Nov 29, 2022 | 121 | Pro Hac Vice Filing fee for M. Carroll, E. Leo, J. Hartman, E. Henningson and A. Goldsmith in the amount of $ 1,000.00 paid. Receipt number WVNC003545. (jb) (Entered: 11/29/2022) (0) |
| Nov 29, 2022 | 123 | Other Document Memorandum of Law in Support of Motion to file under Seal Mylan Opening Claim Construction Brief filed by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 11/29/2022) (5) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Main Document) (30) |
| Nov 29, 2022 | 114 | MOTION for Leave to Appear Pro Hac Vice of Sven Eric Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Attachment WVSB Receipt) (2) |
| Nov 29, 2022 | 114 | MOTION for Leave to Appear Pro Hac Vice of Sven Eric Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Proposed Order) (1) |
| Nov 29, 2022 | 117 | MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Attachment WVSB Receipt) (2) |
| Nov 29, 2022 | 117 | MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Proposed Order) (1) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (15) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (24) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (28) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (30) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (30) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (30) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (14) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (13) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (8) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (9) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (9) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (30) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (8) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (24) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (3) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (4) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (4) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (4) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (16) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (9) |
| Nov 29, 2022 | 124 | REDACTION Regeneron's Opening Claim Construction Brief by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit, # 11 Exhibit, # 12 Exhibit, # 13 Exhibit, # 14 Exhibit, # 15 Exhibit, # 16 Exhibit, # 17 Exhibit, # 18 Exhibit, # 19 Exhibit, # 20 Exhibit, # 21 Exhibit)(Ruby, Steven) (Entered: 11/29/2022) (Exhibit) (10) |
| Nov 29, 2022 | 116 | MOTION for Leave to Appear Pro Hac Vice of Evan T. Leo by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Attachment WVSB Receipt) (2) |
| Nov 29, 2022 | 116 | MOTION for Leave to Appear Pro Hac Vice of Evan T. Leo by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Proposed Order) (1) |
| Nov 29, 2022 | 115 | MOTION for Leave to Appear Pro Hac Vice of Jacob E. Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Attachment WVSB Receipt) (2) |
| Nov 29, 2022 | 115 | MOTION for Leave to Appear Pro Hac Vice of Jacob E. Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Proposed Order) (1) |
| Nov 29, 2022 | 113 | MOTION for Leave to Appear Pro Hac Vice of Andrew E. Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Attachment WVSB Receipt) (2) |
| Nov 29, 2022 | 113 | MOTION for Leave to Appear Pro Hac Vice of Andrew E. Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 11/29/2022) (Proposed Order) (1) |
| Nov 29, 2022 | 118 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment Subpoena)(Pogue, David) (Entered: 11/29/2022) (Attachment Subpoena) (1) |
| Nov 28, 2022 | 110 | ORDER granting 101 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/28/2022. (Copy counsel of record)(jmm) (Entered: 11/28/2022) (1) |
| Nov 28, 2022 | 111 | ORDER granting 100 MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/28/2022. (jmm) (Entered: 11/28/2022) (1) |
| Nov 28, 2022 | 112 | ORDER granting 99 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/28/2022. (jmm) (Entered: 11/28/2022) (1) |
| Nov 23, 2022 | 103 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment)(Ruby, Steven) (Entered: 11/23/2022) (Main Document) (2) |
| Nov 23, 2022 | 104 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment)(Ruby, Steven) (Entered: 11/23/2022) (Main Document) (2) |
| Nov 23, 2022 | 105 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment)(Ruby, Steven) (Entered: 11/23/2022) (Main Document) (2) |
| Nov 23, 2022 | 107 | MEMORANDUM of Law in Support of Motion for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc. . (Pogue, David) (Entered: 11/23/2022) (4) |
| Nov 23, 2022 | 108 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Fourth Request for Production of Documents to Mylan Pharmaceuticals Inc.. (Pogue, David) (Entered: 11/23/2022) (2) |
| Nov 23, 2022 | 109 | CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Pogue, David) (Entered: 11/23/2022) (2) |
| Nov 23, 2022 | 104 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment)(Ruby, Steven) (Entered: 11/23/2022) (Attachment) (1) |
| Nov 23, 2022 | 103 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment)(Ruby, Steven) (Entered: 11/23/2022) (Attachment) (1) |
| Nov 23, 2022 | 105 | NOTICE by Regeneron Pharmaceuticals, Inc. of Service of Subpoena (Attachments: # 1 Attachment)(Ruby, Steven) (Entered: 11/23/2022) (Attachment) (1) |
| Nov 17, 2022 | 102 | JOINT CLAIM CONSTRUCTION CHART Other Document filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 11/17/2022) (16) |
| Nov 15, 2022 | 99 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 99 | Motion for Leave to Appear (Attachment A) (8) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 99 | Motion for Leave to Appear (Attachment WVSB Receipt) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 99 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 100 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 100 | Motion for Leave to Appear (Attachment A) (8) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 100 | Motion for Leave to Appear (Attachment WVSB Receipt) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 100 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 101 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 101 | Motion for Leave to Appear (Attachment A) (8) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 101 | Motion for Leave to Appear (Attachment WVSB Receipt) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 15, 2022 | 101 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment WVSB Receipt, # (3) Proposed Order)(Ruby, Steven) |
| Nov 14, 2022 | 98 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's First Requests for Admission to Mylan Pharmaceuticals Inc.. (Pogue, David) |
| Nov 11, 2022 | 96 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Defendant's Preliminary Constructions and Intrinsic Support). (O'Brien, William) |
| Nov 11, 2022 | 97 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. (Plaintiff's Preliminary Constructions and Intrinsic Support). (Pogue, David) |
| Nov 6, 2022 | 95 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 11.4.22). (O'Brien, William) |
| Nov 4, 2022 | 94 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Third Requests for Production of Documents to Mylan Pharmaceuticals Inc.. (Pogue, David) |
| Nov 2, 2022 | 91 | Protective Order (27) Docket Text: STIPULATED PROTECTIVE ORDER. Signed by Chief District Judge Thomas S Kleeh on 11/2/2022. (jb) |
| Nov 2, 2022 | 92 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. (Ruby, Steven) |
| Nov 2, 2022 | 93 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Mylan Pharmaceuticals Inc.'s First Requests for the Production of Documents and Things to Regeneron (Nos. 1-120). (Pogue, David) |
| Nov 1, 2022 | 89 | Stipulation (Main Document) (2) Docket Text: STIPULATION and Joint Request for Entry of Proposed Protective Order by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order, # (2) Exhibit Ex. A to proposed protective order, # (3) Exhibit Ex. B to proposed protective order)(Copland, Gordon) |
| Nov 1, 2022 | 89 | Stipulation (Proposed Order) (23) Docket Text: STIPULATION and Joint Request for Entry of Proposed Protective Order by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order, # (2) Exhibit Ex. A to proposed protective order, # (3) Exhibit Ex. B to proposed protective order)(Copland, Gordon) |
| Nov 1, 2022 | 89 | Stipulation (Exhibit Ex. A to proposed protective order) (2) Docket Text: STIPULATION and Joint Request for Entry of Proposed Protective Order by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order, # (2) Exhibit Ex. A to proposed protective order, # (3) Exhibit Ex. B to proposed protective order)(Copland, Gordon) |
| Nov 1, 2022 | 89 | Stipulation (Exhibit Ex. B to proposed protective order) (2) Docket Text: STIPULATION and Joint Request for Entry of Proposed Protective Order by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order, # (2) Exhibit Ex. A to proposed protective order, # (3) Exhibit Ex. B to proposed protective order)(Copland, Gordon) |
| Oct 28, 2022 | 88 | Stipulation (3) Docket Text: STIPULATION Regarding Case Narrowing and Injunctive Relief by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) |
| Oct 25, 2022 | 87 | Scheduling Order (2) Docket Text: SCHEDULING ORDER: Amended Pleadings due by 12/9/2022. Joinder of Parties due by 12/9/2022. Markman Hearing set for 1/6/2023 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Fact Discovery due by 1/18/2023. Dispositive Motions due by 4/20/2023. Proposed Pretrial Order due by 5/18/2023. Final Pretrial Conference/Settlement Conference set for 5/30/2023 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Jury Selection and Jury Trial set for 6/12/2023 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 10/25/2022. (dk) |
| Oct 20, 2022 | 85 | Other Document (Main Document) (3) Docket Text: Other Document Post-Hearing Supplement filed by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Attachment Exhibits A & B)(O'Brien, William) |
| Oct 20, 2022 | 85 | Other Document (Attachment Exhibits A & B) (8) Docket Text: Other Document Post-Hearing Supplement filed by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Attachment Exhibits A & B)(O'Brien, William) |
| Oct 20, 2022 | 86 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Mylan Pharmaceuticals Inc.s Responses and Objections to Plaintiffs Second Set of Requests for the Production of Documents (Nos.7-27). (Copland, Gordon) |
| Oct 19, 2022 | 84 | Other Document (Main Document) (3) Docket Text: Other Document Post-Hearing Supplement filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Proposed Order Updated Proposed Scheduling Order)(Ruby, Steven) |
| Oct 19, 2022 | 84 | Other Document (Proposed Order Updated Proposed Scheduling Order) (2) Docket Text: Other Document Post-Hearing Supplement filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Proposed Order Updated Proposed Scheduling Order)(Ruby, Steven) |
| Oct 12, 2022 | 82 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Defendant's Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) on 10.10.22). (O'Brien, William) |
| Oct 12, 2022 | 83 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 10.10.22). (O'Brien, William) |
| Oct 6, 2022 | 81 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (First Requests for the Production of Documents and Things to Regeneron (Nos. 1-120)). (O'Brien, William) |
| Oct 3, 2022 | 79 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. MYLAN PARMACEUTICALS INC.S ANSWERS AND OBJECTIONS TO REGENERONS FIRST SET OF INTERROGATORIES (NOS. 1-2). (Copland, Gordon) |
| Oct 3, 2022 | 80 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. MYLAN PARMACEUTICALS INC.S RESPONSES AND OBJECTIONS TO PLAINTIFFS FIRST SET REQUESTS FOR PRODUCTION OF DOCUMENTS AND THINGS (NOS. 1-6). (Copland, Gordon) |
| Sep 29, 2022 | 77 | Other Document (4) Docket Text: Other Document Defendant Mylan Pharmaceuticals Inc.s Post-Hearing Supplement filed by Mylan Pharmaceuticals Inc.. (Copland, Gordon) |
| Sep 29, 2022 | 78 | Response (Main Document) (5) Docket Text: RESPONSE by Regeneron Pharmaceuticals, Inc. to [77] Other Document. (Attachments: # (1) Proposed Order Proposed Scheduling Order)(Ruby, Steven) |
| Sep 29, 2022 | 78 | Response (Proposed Order Proposed Scheduling Order) (2) Docket Text: RESPONSE by Regeneron Pharmaceuticals, Inc. to [77] Other Document. (Attachments: # (1) Proposed Order Proposed Scheduling Order)(Ruby, Steven) |
| Sep 23, 2022 | 75 | Report of Rule 26(f) Planning Meeting (Main Document) (13) Docket Text: REPORT of Rule 26(f) Planning Meeting. (Attachments: # (1) Exhibit Exhibit A, # (2) Exhibit Exhibit B)(Ruby, Steven) |
| Sep 23, 2022 | 75 | Report of Rule 26(f) Planning Meeting (Exhibit Exhibit A) (1) Docket Text: REPORT of Rule 26(f) Planning Meeting. (Attachments: # (1) Exhibit Exhibit A, # (2) Exhibit Exhibit B)(Ruby, Steven) |
| Sep 23, 2022 | 75 | Report of Rule 26(f) Planning Meeting (Exhibit Exhibit B) (2) Docket Text: REPORT of Rule 26(f) Planning Meeting. (Attachments: # (1) Exhibit Exhibit A, # (2) Exhibit Exhibit B)(Ruby, Steven) |
| Sep 20, 2022 | 72 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [68] Motion of Katie A. Body for Leave to Appear Pro Hac Vice on behalf of Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/20/2022. (dk) |
| Sep 20, 2022 | 73 | Order (2) Docket Text: ORDER SCHEDULING STATUS CONFERENCE for 9/28/2022 02:30 PM, via Zoom videoconferencing, before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 9/20/2022. (dk) |
| Sep 20, 2022 | 74 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Plaintiff's Rule 26(a) Initial Disclosures. (Ruby, Steven) |
| Sep 16, 2022 | 71 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. Regeneron's Second Requests for Production of Documents and things to Mylan Pharmaceuticals Inc. (Ruby, Steven) |
| Sep 15, 2022 | 70 | Answer to Counterclaim (24) Docket Text: Regeneron Pharmaceuticals Inc.'s ANSWER to [47] Answer to Complaint, Counterclaim by Regeneron Pharmaceuticals, Inc..(Ruby, Steven) |
| Sep 13, 2022 | 67 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [56] Motion of Abraham J. Varon for Leave to Appear Pro Hac Vice on behalf of Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/13/2022. (dk) |
| Sep 13, 2022 | 68 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Katie A. Boda) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Sep 13, 2022 | 68 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Katie A. Boda) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Sep 6, 2022 | 57 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [42] Motion for Leave to Appear Pro Hac Vice (Lauren M. Lesko) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 58 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [43] Motion for Leave to Appear Pro Hac Vice (William A. Rakoczy) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 59 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [44] Motion for Leave to Appear Pro Hac Vice (Neil B. McLaughlin) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 60 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [45] Motion for Leave to Appear Pro Hac Vice (Eric R. Hunt) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 61 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [46] Motion for Leave to Appear Pro Hac Vice (Heinz J. Salmen) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 62 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [49] Motion for Leave to Appear Pro Hac Vice (Lawrence Scott Beall) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 63 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [50] Motion for Leave to Appear Pro Hac Vice (Steven J. Birkos) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 64 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [51] Motion for Leave to Appear Pro Hac Vice (Thomas H. Ehrich) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 6, 2022 | 65 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [52] Motion for Leave to Appear Pro Hac Vice (Jeffrey A. Marx) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) |
| Sep 5, 2022 | 56 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Abraham J. Varon) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Sep 5, 2022 | 56 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Abraham J. Varon) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 31, 2022 | 54 | Certificate of Service (1) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. First Set of Interrogatories to Mylan Pharmaceuticals In.c. (Pogue, David) |
| Aug 31, 2022 | 55 | Certificate of Service (1) Docket Text: CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. First Requests for Production to Mylan Pharmaceuticals Inc.. (Pogue, David) |
| Aug 26, 2022 | 49 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Lawrence Scott Beall) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 49 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Lawrence Scott Beall) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 50 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Steven J. Birkos) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 50 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Steven J. Birkos) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 51 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Thomas H. Ehrich) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 51 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Thomas H. Ehrich) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 52 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Jeffrey A. Marx) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 26, 2022 | 52 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Jeffrey A. Marx) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(O'Brien, William) |
| Aug 25, 2022 | 42 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Lauren M. Lesko) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 42 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Lauren M. Lesko) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 43 | Motion for Leave to Appear (Main Document) (4) Docket Text: MOTION for Leave to Appear Pro Hac Vice (William A. Rakoczy) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 43 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (William A. Rakoczy) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 44 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Neil B. McLaughlin) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 44 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Neil B. McLaughlin) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 45 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Eric R. Hunt) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 45 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Eric R. Hunt) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 46 | Motion for Leave to Appear (Main Document) (3) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Heinz J. Salmen) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 46 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice (Heinz J. Salmen) by Mylan Pharmaceuticals Inc.. (Attachments: # (1) Proposed Order)(Copland, Gordon) |
| Aug 25, 2022 | 47 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, , COUNTERCLAIM against Regeneron Pharmaceuticals, Inc. by Mylan Pharmaceuticals Inc..(O'Brien, William) |
| Aug 23, 2022 | 41 | Reply to Response to Motion (10) Docket Text: REPLY to Response to Motion re [7] MOTION for Hearing - Requesting Expedited Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) |
| Aug 22, 2022 | 27 | Notice of Verification of Attorney Admission (1) Docket Text: VERIFICATION OF ATTORNEY ADMISSION issued to Attorneys W. Rakoczy, H. Salmen, E. Hunt, N. McLaughlin, and L. Lesko. (dk) |
| Aug 22, 2022 | 28 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [8] Motion of Arthur J. Argall, III for leave to appear Pro Hac Vice on behaf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 29 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [9] Motion of Adam Pan for leave to appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 30 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [14] Motion of Nicholas W. Jordan for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 31 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [13] Motion of Kathryn S. Kayali for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 32 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [12] Motion of Ellen E. Oberwetter for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 33 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [11] Motion of David I. Berl for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 34 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [10] Motion of Andrew V. Trask for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 35 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [23] Motion of James Evans for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 36 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [22] Motion of Larry Coury for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 37 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [21] Motion of Petra Scamborova for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 38 | Order on Public Motion (1) Docket Text: ORDER granting [17] Motion of Teagan J. Gregory for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 39 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [16] Motion of Thomas S. Fletcher for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 22, 2022 | 40 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER granting [15] Motion of Shaun P. Mahaffy for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) |
| Aug 19, 2022 | 25 | Corporate Disclosure Statement (2) Docket Text: Corporate Disclosure Statement by Mylan Pharmaceuticals Inc. identifying Corporate Parent Mylan Inc., Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc... (O'Brien, William) |
| Aug 19, 2022 | 26 | Response in Opposition to Motion (16) Docket Text: RESPONSE in Opposition re [7] MOTION for Hearing - Requesting Expedited Status Conference filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) |
| Aug 17, 2022 | 21 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Petra Scamborova Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). |
| Aug 17, 2022 | 21 | Motion for Miscellaneous Relief (Attachment WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Petra Scamborova Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). |
| Aug 17, 2022 | 22 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Larry Coury Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). |
| Aug 17, 2022 | 22 | Motion for Miscellaneous Relief (Attachment WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Larry Coury Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). |
| Aug 17, 2022 | 23 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice for James Evans Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). |
| Aug 17, 2022 | 23 | Motion for Miscellaneous Relief (Attachment WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice for James Evans Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). |
| Aug 10, 2022 | 19 | FirstOrder (6) Docket Text: FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 9/9/2022. Rule 26 Meeting Report due by 9/23/2022. Discovery due by 10/10/2022. Signed by Chief District Judge Thomas S Kleeh on 8/10/2022. (dk) |
| Aug 8, 2022 | 8 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Arthur J. Argall III Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 8 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Arthur J. Argall III Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 8 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Arthur J. Argall III Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 9 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Adam Pan Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 9 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Adam Pan Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 9 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Adam Pan Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 10 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Andrew V. Trask Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 10 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Andrew V. Trask Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 10 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Andrew V. Trask Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 11 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of David I. Berl Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment B, # (3) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 11 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of David I. Berl Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment B, # (3) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 11 | Motion for Miscellaneous Relief (Attachment B) (1) Docket Text: Application for Admission Pro Hac Vice of David I. Berl Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment B, # (3) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 11 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of David I. Berl Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Attachment B, # (3) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 12 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Ellen E. Oberwetter Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 12 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Ellen E. Oberwetter Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 12 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Ellen E. Oberwetter Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 13 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Kathryn S. Kayali Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 13 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Kathryn S. Kayali Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 13 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Kathryn S. Kayali Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 14 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Nicholas W. Jordan Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 14 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Nicholas W. Jordan Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 14 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Nicholas W. Jordan Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 15 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Shaun P. Mahaffy Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 15 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Shaun P. Mahaffy Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 15 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Shaun P. Mahaffy Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 16 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Thomas S. Fletcher Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 16 | Motion for Miscellaneous Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Thomas S. Fletcher Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 16 | Motion for Miscellaneous Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Thomas S. Fletcher Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 17 | Public Motion for Misc Relief (Main Document) (3) Docket Text: Application for Admission Pro Hac Vice of Teagan J. Gregory Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 17 | Public Motion for Misc Relief (Attachment A) (7) Docket Text: Application for Admission Pro Hac Vice of Teagan J. Gregory Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 17 | Public Motion for Misc Relief (Exhibit WVSB Receipt) (2) Docket Text: Application for Admission Pro Hac Vice of Teagan J. Gregory Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # (1) Attachment A, # (2) Exhibit WVSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). |
| Aug 8, 2022 | 18 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by Gordon H. Copland on behalf of Mylan Pharmaceuticals Inc. (Copland, Gordon) |
| Aug 5, 2022 | 7 | Motion for Hearing (8) Docket Text: MOTION for Hearing - Requesting Expedited Status Conference by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) |
| Aug 4, 2022 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed as to Mylan Pharmaceuticals Inc. served on 8/4/2022. (Pogue, David) |
| Aug 3, 2022 | 2 | Notice of Verification of Attorney Admission (1) Docket Text: VERIFICATION OF ATTORNEY ADMISSION issued to D. Berl, E. Oberwetter, T. Fletcher, A. Trask, T. Gregory, S. Mahaffy, K. Kayali, A. Argall, A. Pan, and N. Jordan. (dk) |
| Aug 3, 2022 | 3 | Report Re: Patent/Trademark (2) Docket Text: REPORT to USPTO on the filing or determination of an action regarding re [1] Complaint. (dk) |
| Aug 3, 2022 | 5 | Corporate Disclosure Statement (2) Docket Text: Corporate Disclosure Statement by Regeneron Pharmaceuticals, Inc.. (Pogue, David) |
| Aug 2, 2022 | 1 | Complaint* (1) |
| Aug 2, 2022 | 1 | Complaint (Main Document) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 1 - US Patent 7,070,959 B1) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 2 - US Patent 9,222,106 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 3 - US Patent 9,254,338 B2) (15) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 4 - US Patent 9,669,069 B2) (15) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 5 - US Patent 9,816,110 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 6 - US Patent 10,130,681 B2) (16) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 7 - US Patent 10,406,226 B2) (13) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 8 - US Patent 10,415,055 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 9 - US Patent 10,464,992 B2) (12) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 10 - US Patent 10,669,594 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 11 - US Patent 10,857,205 B2) (21) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 12 - US Patent 10,888,601 B2) (22) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 13 - US Patent 10,927,342 B2) (24) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 14 - US Patent 10,973,879 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 15 - US Patent 11,053,280 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 16 - US Patent 11,066,458 B2) (14) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 17 - US Patent 11,084,865 B2) (14) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 18 - US Patent 11,104,715 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 19 - US Patent 11,174,283 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 20 - US Patent 11,186,625 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 21 - US Patent 11,253,572 B2) (26) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 22 - US Patent 11,299,532 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 23 - US Patent 11,306,135 B2) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Exhibit 24 - US Patent 11,332,771 B2) (17) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Civil Cover Sheet) (1) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
| Aug 2, 2022 | 1 | Complaint (Proposed AO120 Form) (1) Docket Text: COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee $402. Receipt #AWVNDC-3522822. (Attachments: # (1) Exhibit 1 - US Patent 7,070,959 B1, # (2) Exhibit 2 - US Patent 9,222,106 B2, # (3) Exhibit 3 - US Patent 9,254,338 B2, # (4) Exhibit 4 - US Patent 9,669,069 B2, # (5) Exhibit 5 - US Patent 9,816,110 B2, # (6) Exhibit 6 - US Patent 10,130,681 B2, # (7) Exhibit 7 - US Patent 10,406,226 B2, # (8) Exhibit 8 - US Patent 10,415,055 B2, # (9) Exhibit 9 - US Patent 10,464,992 B2, # (10) Exhibit 10 - US Patent 10,669,594 B2, # (11) Exhibit 11 - US Patent 10,857,205 B2, # (12) Exhibit 12 - US Patent 10,888,601 B2, # (13) Exhibit 13 - US Patent 10,927,342 B2, # (14) Exhibit 14 - US Patent 10,973,879 B2, # (15) Exhibit 15 - US Patent 11,053,280 B2, # (16) Exhibit 16 - US Patent 11,066,458 B2, # (17) Exhibit 17 - US Patent 11,084,865 B2, # (18) Exhibit 18 - US Patent 11,104,715 B2, # (19) Exhibit 19 - US Patent 11,174,283 B2, # (20) Exhibit 20 - US Patent 11,186,625 B2, # (21) Exhibit 21 - US Patent 11,253,572 B2, # (22) Exhibit 22 - US Patent 11,299,532 B2, # (23) Exhibit 23 - US Patent 11,306,135 B2, # (24) Exhibit 24 - US Patent 11,332,771 B2, # (25) Civil Cover Sheet, # (26) Proposed AO120 Form)(dk) |
